[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Coapt LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":249},{"warningLetters":4,"total":248},[5,30,51,70,95,113,135,156,175,191,207,224],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":24,"medical_device_id":19,"response_letter_date":19},2938,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-01-06T20:00:00Z\">01\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-06T05:00:00Z\">01\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-coast-vapor-company-622120-01062022\">South Coast Vapor Company\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Raymond\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>South Coast Vapor Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1485 Poinsettia Ave Ste 112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vista\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92081-8537\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jimmy@yougotejuice.com\"> jimmy@yougotejuice.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 06, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Raymond:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records and determined that South Coast Vapor Company manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States YOU GOT E-JUICE PAPAYA PEACH ON ICE 3MG 60ML e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 2,800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002388, on September 9, 2020. However, FDA issued a negative action for STN PM0002388 in the form of a Marketing Denial Order determination on September 9, 2021, which covers 2,046 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002388 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100353, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames Raymond\n\nRecipient Title\n\nCEO\n\nSouth Coast Vapor Company\n\n1485 Poinsettia Ave Ste 112\n\nVista, CA 92081-8537\n\nUnited States\n\njimmy@yougotejuice.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJanuary 06, 2022\n\nWARNING LETTER\n\nDear Mr. Raymond:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records and determined that South Coast Vapor Company manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States YOU GOT E-JUICE PAPAYA PEACH ON ICE 3MG 60ML e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 2,800 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0002388, on September 9, 2020. However, FDA issued a negative action for STN PM0002388 in the form of a Marketing Denial Order determination on September 9, 2021, which covers 2,046 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0002388 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100353, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","South Coast Vapor Company","south-coast-vapor-company-622120-01062022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsouth-coast-vapor-company-622120-01062022","2026-10-26T08:10:01.932435+00:00","Warning Letter","Issued","2022-01-06","622120","Tobacco","James Raymond","2026-08-20T02:17:27.29+00:00","VIA UPS and Electronic Mail",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":18,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":46,"closeout_date":19,"issuing_office":36,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},2652,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2022-05-24T13:20:00Z\">05\u002F24\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-11T04:00:00Z\">05\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoastal-fresh-farms-inc-629333-05112022\">Coastal Fresh Farms, Inc.\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leonard T. Cole\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Coastal Fresh Farms, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3625 E Thousand Oaks Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ste 243\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Westlake Village\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91362-3500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Cole:\u003C\u002Fp>\n\n\u003Cp>On January 31 through February 9, 2022, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Coastal Fresh Farms, Inc. located at 3625 E Thousand Oaks Blvd Ste 243, Westlake Village, CA 91362-3500. We also conducted an inspection on August 14 – 21, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffoodsafety- modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-foodhumans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form FDA 483a issued on February 9, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any foods that you import, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Coriander imported from \u003Cstrong>(b) (4)\u003C\u002Fstrong> ;\u003C\u002Fli>\n\t\u003Cli>Green onion imported from&nbsp;\u003Cstrong>(b) (4)\u003C\u002Fstrong> ;\u003C\u002Fli>\n\t\u003Cli>and\u003C\u002Fli>\n\t\u003Cli>Parsley curly imported from&nbsp;\u003Cstrong>(b) (4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>During our August 2020 inspection, you provided a one-page Standard Operating Procedure (SOP) titled “FSMA-VENDOR APPROVAL,” dated January 23, 2020, and various audit reports from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). During the most recent inspection, you did not provide any documents related to an FSVP. On February 2, 2022, you sent us an email indicating your intent to meet with a food safety consultant to “discuss putting together an FSVP program.” Therefore, at the conclusion of this inspection we found that you were not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>You import raw agricultural commodity produce, which is “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate your supplier is in compliance with the requirements of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, 1 World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #629333 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nLeonard T. Cole\n\nRecipient Title\n\nPresident\n\nCoastal Fresh Farms, Inc.\n\n3625 E Thousand Oaks Blvd\n\nSte 243\n\nWestlake Village, CA 91362-3500\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nDear Mr. Cole:\n\nOn January 31 through February 9, 2022, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Coastal Fresh Farms, Inc. located at 3625 E Thousand Oaks Blvd Ste 243, Westlake Village, CA 91362-3500. We also conducted an inspection on August 14 – 21, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffoodsafety- modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-foodhumans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\n\nWe have not received your response to the Form FDA 483a issued on February 9, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop, maintain, and follow an FSVP for any foods that you import, including:\n\nCoriander imported from (b) (4) ;\n\nGreen onion imported from (b) (4) ;\n\nand\n\nParsley curly imported from (b) (4)\n\nDuring our August 2020 inspection, you provided a one-page Standard Operating Procedure (SOP) titled “FSMA-VENDOR APPROVAL,” dated January 23, 2020, and various audit reports from your foreign suppliers. However, the documents that are relevant to an FSVP are incomplete, and you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). During the most recent inspection, you did not provide any documents related to an FSVP. On February 2, 2022, you sent us an email indicating your intent to meet with a food safety consultant to “discuss putting together an FSVP program.” Therefore, at the conclusion of this inspection we found that you were not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nAdditionally, we offer the following comment:\n\nYou import raw agricultural commodity produce, which is “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate your supplier is in compliance with the requirements of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Nabeela J. Chaudhry, Compliance Officer, Division of West Coast Imports, 1 World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Nabeela Chaudhry via email at nabeela.chaudhry@fda.hhs.gov. Please reference CMS #629333 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Coastal Fresh Farms, Inc.","coastal-fresh-farms-inc-629333-05112022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoastal-fresh-farms-inc-629333-05112022","2026-10-26T08:08:16.591106+00:00","2022-05-24","629333","Food & Beverages","Leonard T. Cole","2026-08-20T01:52:50.062+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-05-11",{"id":52,"raw":53,"subject":12,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":61,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":65,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":66,"body_fetched_at":67,"delivery_method":29,"recipient_title":19,"reference_number":68,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},1424,[54,55,56,11,12,13,13,13],"\u003Ctime datetime=\"2024-06-13T04:00:00Z\">06\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-12T04:00:00Z\">06\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-vape-supply-inc-685567-06122024\">West Coast Vape Supply, Inc\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402158\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alham Benyameen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>West Coast Vape Supply, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15321 Transistor Ln.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huntington Beach\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92649\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@westcoastvapesupply.com\"> support@westcoastvapesupply.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Alham Benyameen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestcoastvapesupply.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip Ejuice by Bad Drip 60ML, Don’t Care Bear Ejuice by Bad Drip 60ML, and Funky Republic FI3000 Disposable Vape 3000 Puffs - Apple Watermelon.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685567.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685567-2.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402158, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Atencio\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\n580 W. Cheyenne #160\u003Cbr>\nNorth Las Vegas, NV 89030\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\n5445 Oceanus Dr. #102\u003Cbr>\nHuntington Beach, CA 92649\u003C\u002Fp>\n\n\u003Cp>Alham Benyameen\u003Cbr>\n16541 Gothard St., Ste. 201\u003Cbr>\nHuntington Beach CA 92657\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\nc\u002Fo Registered Agents, Inc.\u003Cbr>\n401 Ryland St., Ste. 200\u003Cbr>\nReno, NV 89502\u003C\u002Fp>\n\n\u003Cp>GoDaddy, Inc.\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402158\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAlham Benyameen\n\nWest Coast Vape Supply, Inc\n\n15321 Transistor Ln.\n\nHuntington Beach, CA 92649\n\nUnited States\n\nsupport@westcoastvapesupply.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 12, 2024\n\nWARNING LETTER\n\nDear Alham Benyameen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestcoastvapesupply.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip Ejuice by Bad Drip 60ML, Don’t Care Bear Ejuice by Bad Drip 60ML, and Funky Republic FI3000 Disposable Vape 3000 Puffs - Apple Watermelon.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402158, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Atencio\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nWest Coast Vape Supply, Inc.\n\n580 W. Cheyenne #160\n\nNorth Las Vegas, NV 89030\n\nWest Coast Vape Supply, Inc.\n\n5445 Oceanus Dr. #102\n\nHuntington Beach, CA 92649\n\nAlham Benyameen\n\n16541 Gothard St., Ste. 201\n\nHuntington Beach CA 92657\n\nWest Coast Vape Supply, Inc.\n\nc\u002Fo Registered Agents, Inc.\n\n401 Ryland St., Ste. 200\n\nReno, NV 89502\n\nGoDaddy, Inc.\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","West Coast Vape Supply, Inc","west-coast-vape-supply-inc-685567-06122024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-vape-supply-inc-685567-06122024","2026-10-26T08:10:31.144987+00:00","2024-06-13","685567","Alham Benyameen","2026-08-20T00:02:37.36+00:00","RW2402158","2024-06-12",{"id":71,"raw":72,"subject":77,"body_html":79,"body_text":80,"firm_name":81,"letter_id":82,"created_at":83,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":86,"posted_date":87,"marcs_cms_no":88,"product_type":46,"closeout_date":89,"issuing_office":90,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1676,[73,74,75,76,77,13,78,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-05T05:00:00Z\">12\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fus-gulf-coast-trading-co-inc-668767-12052023\">US Gulf Coast Trading Co., Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations West III","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fu-s-gulf-coast-trading-co-inc-668767-07112024\">\u003Ctime datetime=\"2024-07-17T04:00:00Z\">07\u002F17\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Overnight\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Abdallah K. Yassir\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Partner and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>US Gulf Coast Trading Co., Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14100 Auto Park Way Ste. I\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77083-5887\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS #668767\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Yassir:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your refrigerated, frozen, and ambient food product warehouse located at 14100 Auto Park Way Ste. I, Houston, TX on August 7 through 15, 2023. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule) in Title 21, Code of Regulations, Part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your firm. In addition, during the inspection, FDA collected filth samples from various areas within your warehouse facility, and the analytical results revealed rodent filth present throughout your facility.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the food products warehoused in your facility are adulterated within the meaning of section 402(a)(3) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(3)] because they consist in whole or in part of any filthy, putrid, or decomposed substance, or are otherwise unfit for food, and section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act and FDA regulations through links in FDA's Internet home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We received your responses via email on August 22, 2023, and September 13, 2023, which included pest control reports, photos and video documenting the disposing of product in the dumpster, warehouse inspection sheets, and other warehouse photos. After reviewing the inspectional findings and responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your responses below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not exclude pests from your food plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, our investigators observed evidence of rodent activity, including rodent excreta pellets (REPs) in numbers too numerous to count (TNTC), gnaw marks in food and food packaging, nesting material, live maggots, and other apparent excrement throughout your facility, including areas where human food is routinely stored. Below are some examples of the observations made by the investigators:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse:\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On August 7, 2023, greater than 50 REPs on the floor along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bay door. Food products such as herbal tea, tortillas, pomegranate sauce, basmati rice, and dried mallow were stored within 3ft of this door.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, TNTC REPs and seven other apparent excrement in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner, behind boxes containing packaged herbal tea stacked on a pallet.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, greater than 100 REPs along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> wall behind a pallet containing boxes with tortillas, loose tortillas, and boxes containing pomegranate sauce.\u003C\u002Fli>\n\t\u003Cli>On August 8, 2023, numerous REPs on top of and along seams of 20 lb. burlap bags containing long grain steamed basmati rice, located in section \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 8, 2023, REPs, gnaw holes, and nesting materials on boxes and packaging containing dried mallow, located in section \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 8, 2023, numerous REPs, rodent gnawed material, and live maggots on and inside packages of tortillas located in section \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>\u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse:\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On August 7, 2023, greater than 50 REPs behind a pallet of boxes containing jarred pickled cucumbers in the middle and on the bottom of row \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, greater than 50 REPs behind a pallet containing boxed canned black olives in the middle bottom of row \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, TNTC REPs at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> corner, adjacent to the office entry, and on a pallet containing instant noodles.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, approximately 20 REPs on top of boxes containing white vinegar and tahini at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> end bottom of row \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>\u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse:\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On August 7, 2023, approximately 40 REPs on the floor around a pallet containing packages of jarred jam and black olive slices at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> end, located on the bottom of row \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, TNTC REPs on the floor next to a pallet of packaged and jarred jam and black olives slices at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> end, located on the bottom of row \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>On August 9, 2023, TNTC maggots on, underneath, and behind a pallet containing canned pepper molasses, flavored rose water, canned liquid Jameed yogurt soup, and pomegranate sauce located in section \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>\u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse:\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On August 7, 2023, greater than 100 REPs on top of two pallets containing packaged cooked chickpeas stored adjacent to the employee restroom.\u003C\u002Fli>\n\t\u003Cli>On August 7, 2023, TNTC REPs behind the two pallets of cooked chickpeas stored adjacent to the employee restroom.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In addition to visual observations, FDA collected several samples during the inspection. These samples included food products (samples 1231696, 1231697, and 1231698) and a filth sample (sample 1231695). These samples were submitted to FDA labs for analysis, which confirmed the presence of REPs, rodent gnaw marks in the packaging, and\u002For rodent hairs in these samples. Further, the filth sample included REPs and rodent-gnawed materials collected from various areas of the warehouse, demonstrating that rodent activity existed throughout your facility.\u003C\u002Fp>\n\n\u003Cp>2. You did not maintain your plant in adequate repair, as required by 21 CFR § 117.35(a). Specifically, gaps were observed along the bottom, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and top of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bay door when the door was fully closed. The roll-up door opens directly to the exterior \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse, which could allow for the entrance of pests into the facility. Food products such as packaged tortillas, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, herbal tea, and stuffed eggplant were stored directly approximately 3 feet to this bay door.\u003C\u002Fp>\n\n\u003Cp>3. You did not clean your non-food contact surface in a manner and as frequently as necessary to protect against allergen cross-contact and against contamination, as required by 21 CFR § 117.35(e). Specifically, the exterior wall of the refrigerator located at sections \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse was observed to contain streaks from a tahini spill. The tahini was observed spilled onto the product below, wall, and floor. The tahini product, which is made from sesame seeds, a known allergen, was stored on a rack above other products such as broad fava beans and a pallet which contained canned pepper molasses, flavored rose water, canned liquid yogurt soup, and pomegranate sauce.\u003C\u002Fp>\n\n\u003Cp>4. You did not store food under conditions that protect against contamination of food, as required by 21 CFR § 117.93. Specifically, on August 7-10 and 15, 2023, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bay door, \u003Cstrong>(b)(4)\u003C\u002Fstrong> bay door, and entry door into the warehouse in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> wall remained open when not in use and for extended periods. These conditions could allow for the entrance of pests into your facility, which may cause contamination of food products stored inside the warehouse.\u003C\u002Fp>\n\n\u003Cp>5. You did not keep the grounds around your plant in a condition that would protect against the contamination of food, as required by 21 CFR § 117.20(a). Specifically, during the inspection, FDA investigators observed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On August 7-10 and 15, 2023, numerous empty pallets being stored directly against the exterior corner of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> wall, directly adjacent to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bay door, which remained open when not in use and for extended periods of time during the inspection.\u003C\u002Fli>\n\t\u003Cli>On August 7-10 and 15, 2023, the grass and weeds located at the back and east side of the facility were observed to be overgrown that may lead to the harborage of pests.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These conditions could allow for the contamination of food products stored inside the warehouse.\u003C\u002Fp>\n\n\u003Cp>6. You did not store a toxic chemical in a manner that protects against contamination, as required by 21 CFR § 117.35(b)(2). Specifically, on August 7-10, 2023, a container of insect killer was observed being stored directly adjacent to a pallet containing boxes of jarred jam and canned olives at the end of row \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the warehouse and 20 lb. sacks of steamed basmati rice approximately 8 ft. away along the \u003Cstrong>(b)(4)\u003C\u002Fstrong> wall of the warehouse.\u003C\u002Fp>\n\n\u003Cp>Your responses, dated August 21, 2023 and September 13, 2023, do not clearly demonstrate that your warehouse’s pest control issues are under control and the affected food products were voluntarily destroyed, the gaps in the warehouse doors have been repaired, the pallets have been removed, and the overgrown grass has been trimmed. Additionally, your facility’s most recent \u003Cstrong>(b)(4)\u003C\u002Fstrong> pest control report appears to only address “German Roaches” and “Crazy Ants” activity in the warehouse. There is no mention in the report regarding inspection for rodent activity or treatment\u002Fprevention services conducted for the control of rodents, e.g., placement of bait stations, bait replacement, monitoring, etc. Further, the technician documented in his report, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that your warehouse’s doors were left open during his visit, and he made a recommendation to keep the doors closed when not in use.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action including, but not limited to, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing within 15 working days of receipt of this letter, of the specific steps you have taken to correct violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the food products warehoused in your facility are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time frame within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to René R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308-1425.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003C\u002Fp>\n\n\u003Cp>Cc: Texas Department of State Health Services\u003Cbr>\nLori Woznicki, M.P.H.\u003Cbr>\nFood and Drug Inspections Branch Manager\u003Cbr>\n1100 West 49th Street\u003Cbr>\nAustin, TX 78756\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Overnight\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAbdallah K. Yassir\n\nRecipient Title\n\nManaging Partner and Co-Owner\n\nUS Gulf Coast Trading Co., Inc.\n\n14100 Auto Park Way Ste. I\n\nHouston, TX 77083-5887\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 5, 2023\n\nWARNING LETTER\n\nCMS #668767\n\nDear Mr. Yassir:\n\nThe United States Food and Drug Administration (FDA) inspected your refrigerated, frozen, and ambient food product warehouse located at 14100 Auto Park Way Ste. I, Houston, TX on August 7 through 15, 2023. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule) in Title 21, Code of Regulations, Part 117 (21 CFR part 117). At the conclusion of the inspection, FDA issued a Form FDA 483, Inspectional Observations, listing deviations found at your firm. In addition, during the inspection, FDA collected filth samples from various areas within your warehouse facility, and the analytical results revealed rodent filth present throughout your facility.\n\nBased on FDA’s inspectional findings, we have determined that the food products warehoused in your facility are adulterated within the meaning of section 402(a)(3) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(3)] because they consist in whole or in part of any filthy, putrid, or decomposed substance, or are otherwise unfit for food, and section 402(a)(4) of the Act [21 U.S.C. § 342(a)(4)] because they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act and FDA regulations through links in FDA's Internet home page at http:\u002F\u002Fwww.fda.gov.\n\nWe received your responses via email on August 22, 2023, and September 13, 2023, which included pest control reports, photos and video documenting the disposing of product in the dumpster, warehouse inspection sheets, and other warehouse photos. After reviewing the inspectional findings and responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your responses below.\n\nCurrent Good Manufacturing Practice (21 CFR part 117, Subpart B):\n\n1. You did not exclude pests from your food plant to protect against contamination of food, as required by 21 CFR § 117.35(c). Specifically, our investigators observed evidence of rodent activity, including rodent excreta pellets (REPs) in numbers too numerous to count (TNTC), gnaw marks in food and food packaging, nesting material, live maggots, and other apparent excrement throughout your facility, including areas where human food is routinely stored. Below are some examples of the observations made by the investigators:\n\n(b)(4) of the warehouse:\n\nOn August 7, 2023, greater than 50 REPs on the floor along the (b)(4) bay door. Food products such as herbal tea, tortillas, pomegranate sauce, basmati rice, and dried mallow were stored within 3ft of this door.\n\nOn August 7, 2023, TNTC REPs and seven other apparent excrement in the (b)(4) corner, behind boxes containing packaged herbal tea stacked on a pallet.\n\nOn August 7, 2023, greater than 100 REPs along the (b)(4) wall behind a pallet containing boxes with tortillas, loose tortillas, and boxes containing pomegranate sauce.\n\nOn August 8, 2023, numerous REPs on top of and along seams of 20 lb. burlap bags containing long grain steamed basmati rice, located in section (b)(4).\n\nOn August 8, 2023, REPs, gnaw holes, and nesting materials on boxes and packaging containing dried mallow, located in section (b)(4).\n\nOn August 8, 2023, numerous REPs, rodent gnawed material, and live maggots on and inside packages of tortillas located in section (b)(4).\n\n(b)(4) of the warehouse:\n\nOn August 7, 2023, greater than 50 REPs behind a pallet of boxes containing jarred pickled cucumbers in the middle and on the bottom of row (b)(4).\n\nOn August 7, 2023, greater than 50 REPs behind a pallet containing boxed canned black olives in the middle bottom of row (b)(4).\n\nOn August 7, 2023, TNTC REPs at the (b)(4) corner, adjacent to the office entry, and on a pallet containing instant noodles.\n\nOn August 7, 2023, approximately 20 REPs on top of boxes containing white vinegar and tahini at the (b)(4) end bottom of row (b)(4).\n\n(b)(4) of the warehouse:\n\nOn August 7, 2023, approximately 40 REPs on the floor around a pallet containing packages of jarred jam and black olive slices at the (b)(4) end, located on the bottom of row (b)(4).\n\nOn August 7, 2023, TNTC REPs on the floor next to a pallet of packaged and jarred jam and black olives slices at the (b)(4) end, located on the bottom of row (b)(4).\n\nOn August 9, 2023, TNTC maggots on, underneath, and behind a pallet containing canned pepper molasses, flavored rose water, canned liquid Jameed yogurt soup, and pomegranate sauce located in section (b)(4).\n\n(b)(4) of the warehouse:\n\nOn August 7, 2023, greater than 100 REPs on top of two pallets containing packaged cooked chickpeas stored adjacent to the employee restroom.\n\nOn August 7, 2023, TNTC REPs behind the two pallets of cooked chickpeas stored adjacent to the employee restroom.\n\nIn addition to visual observations, FDA collected several samples during the inspection. These samples included food products (samples 1231696, 1231697, and 1231698) and a filth sample (sample 1231695). These samples were submitted to FDA labs for analysis, which confirmed the presence of REPs, rodent gnaw marks in the packaging, and\u002For rodent hairs in these samples. Further, the filth sample included REPs and rodent-gnawed materials collected from various areas of the warehouse, demonstrating that rodent activity existed throughout your facility.\n\n2. You did not maintain your plant in adequate repair, as required by 21 CFR § 117.35(a). Specifically, gaps were observed along the bottom, (b)(4), and top of the (b)(4) bay door when the door was fully closed. The roll-up door opens directly to the exterior (b)(4) of the warehouse, which could allow for the entrance of pests into the facility. Food products such as packaged tortillas, (b)(4), herbal tea, and stuffed eggplant were stored directly approximately 3 feet to this bay door.\n\n3. You did not clean your non-food contact surface in a manner and as frequently as necessary to protect against allergen cross-contact and against contamination, as required by 21 CFR § 117.35(e). Specifically, the exterior wall of the refrigerator located at sections (b)(4) and (b)(4) of the warehouse was observed to contain streaks from a tahini spill. The tahini was observed spilled onto the product below, wall, and floor. The tahini product, which is made from sesame seeds, a known allergen, was stored on a rack above other products such as broad fava beans and a pallet which contained canned pepper molasses, flavored rose water, canned liquid yogurt soup, and pomegranate sauce.\n\n4. You did not store food under conditions that protect against contamination of food, as required by 21 CFR § 117.93. Specifically, on August 7-10 and 15, 2023, the (b)(4) bay door, (b)(4) bay door, and entry door into the warehouse in the (b)(4) of the (b)(4) wall remained open when not in use and for extended periods. These conditions could allow for the entrance of pests into your facility, which may cause contamination of food products stored inside the warehouse.\n\n5. You did not keep the grounds around your plant in a condition that would protect against the contamination of food, as required by 21 CFR § 117.20(a). Specifically, during the inspection, FDA investigators observed:\n\nOn August 7-10 and 15, 2023, numerous empty pallets being stored directly against the exterior corner of the (b)(4) wall, directly adjacent to the (b)(4) bay door, which remained open when not in use and for extended periods of time during the inspection.\n\nOn August 7-10 and 15, 2023, the grass and weeds located at the back and east side of the facility were observed to be overgrown that may lead to the harborage of pests.\n\nThese conditions could allow for the contamination of food products stored inside the warehouse.\n\n6. You did not store a toxic chemical in a manner that protects against contamination, as required by 21 CFR § 117.35(b)(2). Specifically, on August 7-10, 2023, a container of insect killer was observed being stored directly adjacent to a pallet containing boxes of jarred jam and canned olives at the end of row (b)(4) of the warehouse and 20 lb. sacks of steamed basmati rice approximately 8 ft. away along the (b)(4) wall of the warehouse.\n\nYour responses, dated August 21, 2023 and September 13, 2023, do not clearly demonstrate that your warehouse’s pest control issues are under control and the affected food products were voluntarily destroyed, the gaps in the warehouse doors have been repaired, the pallets have been removed, and the overgrown grass has been trimmed. Additionally, your facility’s most recent (b)(4) pest control report appears to only address “German Roaches” and “Crazy Ants” activity in the warehouse. There is no mention in the report regarding inspection for rodent activity or treatment\u002Fprevention services conducted for the control of rodents, e.g., placement of bait stations, bait replacement, monitoring, etc. Further, the technician documented in his report, dated (b)(4), that your warehouse’s doors were left open during his visit, and he made a recommendation to keep the doors closed when not in use.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including applicable FDA regulations.\n\nYou should take prompt action to correct the violations cited in this letter. Failure to adequately address this matter may result in legal action including, but not limited to, seizure and injunction.\n\nPlease notify FDA in writing within 15 working days of receipt of this letter, of the specific steps you have taken to correct violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that the food products warehoused in your facility are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time frame within which you will do so.\n\nYour written response should be sent to René R. Ramirez, Compliance Officer, U.S. Food and Drug Administration, 1201 North Main Street, Suite 7200, Dallas, TX 75202. If you have questions regarding any issues in this letter, please contact Mr. Ramirez at rene.ramirez@fda.hhs.gov or (210) 308-1425.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nCc: Texas Department of State Health Services\n\nLori Woznicki, M.P.H.\n\nFood and Drug Inspections Branch Manager\n\n1100 West 49th Street\n\nAustin, TX 78756","US Gulf Coast Trading Co., Inc.","us-gulf-coast-trading-co-inc-668767-12052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fus-gulf-coast-trading-co-inc-668767-12052023","2026-10-26T08:10:18.241695+00:00","Closed Out","2023-12-26","668767","2024-07-17","Division of Human and Animal Food Operations West III","Abdallah K. Yassir","2026-08-20T00:25:29.9+00:00","UPS Overnight","2023-12-05",{"id":96,"raw":97,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":61,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":111,"body_fetched_at":112,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":69,"medical_device_id":19,"response_letter_date":19},1357,[98,55,99,100,101,13,13,13],"\u003Ctime datetime=\"2024-07-23T13:20:00Z\">07\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-laboratories-inc-672954-06122024\">West Coast Laboratories, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert P. Bailly\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Acting CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>West Coast Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>116 E. Alondra Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gardena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90248-2806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2024\u003C\u002Fp>\n\n\u003Cp>WL 672954\u003Cbr>\n\u003Cbr>\nDear Mr. Bailly:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 116 E. Alondra Blvd., Gardena, CA from October 3 through October 24, 2023. Based on the inspectional findings we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on October 24, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 15, December 1, and December 7, 2023. Your November 15 and December 1, 2023, communications did not address the specific observations. We address your December 7, 2023, response below, where relevant.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from October 3, 2023, through October 24, 2023, identified serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Calcium Pyruvate, Chromium Picolinate, and CalComplex products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not conduct at least one appropriate test or examination to verify the identity of a dietary ingredient, prior to its use, as required by 21 CFR 111.75(a)(1)(i), nor did you petition the agency under 21 CFR 111.75(a)(1)(ii) for exemption from such testing.\u003Cbr>\n\u003Cbr>\nSpecifically, you did not conduct identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Naticol HPMG Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Aquamin F \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex Lot 523008; you did not conduct identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Chromium Picolinate Lot 40223; nor did you conduct identity testing for Calcium Pyruvate Lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> or Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Calcium Pyruvate Lot 150822. You also have not petitioned the agency for an exemption for such testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you provided revised raw material specifications for Aquamin F, Calcium Pyruvate, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Naticol HPMG. Each of these documents purports to establish a specification of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> match by FTIR. However, you did not provide test records to support that you are conducting identity testing in accordance with the established identity specifications for each of these components.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. For \u003Cstrong>(b)(4)\u003C\u002Fstrong> you do not have specifications to ensure the purity, strength, and composition of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>b. For Naticol HPMG you do not have specifications to ensure the purity, strength, and composition of proteins used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>c. For Aquamin F you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>d. For \u003Cstrong>(b)(4)\u003C\u002Fstrong> you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the Chromium Picolinate dietary supplement.\u003C\u002Fp>\n\n\u003Cp>e. For Calcium Pyruvate you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Calcium Pyruvate.\u003C\u002Fp>\n\n\u003Cp>In addition to establishing these specifications, you must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, which included revised specifications for the ingredients Calcium Pyruvate, \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and finished product specifications for Chromium Picolinate, CalComplex, and Calcium Pyruvate. Your revised specifications do not meet the requirements of 21 CFR 111.70(b)(2) in that they do not include appropriate specifications to ensure the purity and composition of Chromium Picolinate, Calcium Pyruvate and CalComplex.\u003C\u002Fp>\n\n\u003Cp>3. Your quality control approved and released for distribution a batch of dietary supplement for which a component in the batch did not meet its identity specification, as required by 21 CFR 111.123(b)(1). Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Analytical\u002FChemical Certificate of Analysis dated 9\u002F23\u002F22 for Calcium Pyruvate Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes an out-of-specification result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Calcium. The specification is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The ingredient was used in the manufacture of Calcium Pyruvate Lot 150822 on 9\u002F9\u002F22, which was prior to testing. Your quality control approved and released the batch on 10\u002F21\u002F22.\u003C\u002Fp>\n\n\u003Cp>4. Your quality control operations failed to approve and release all components from quarantine before they are used in the manufacture of a dietary supplement, as required by 21 CFR 111.120(e). Specifically, you used the following components in manufacture before your quality control personnel approved and released them from quarantine:\u003C\u002Fp>\n\n\u003Cp>a. You used Aquamin F Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 6\u002F28\u002F23 in the manufacture of CalComplex Lot 523008; however, the dietary ingredient was not approved and released from quarantine until 10\u002F10\u002F23.\u003C\u002Fp>\n\n\u003Cp>b. You used Calcium Pyruvate Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 9\u002F8\u002F22 in the manufacture of Calcium Pyruvate Lot 150822; however, the dietary ingredient was not approved and released from quarantine until 9\u002F26\u002F22.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you state you investigated and concluded that personnel turnover and insufficient training was the most probable cause of the component’s documented release timing delay. Additionally, you state CalComplex Lot 523008 and Calcium Pyruvate Lot 150822 met all strength claims. You provided finished product strength test results for CalComplex Lot 523008 and Calcium Pyruvate Lot 150822, updated procedure 12-D-01 (Raw material Component Identity Testing), and staff training records; however, you did not provide documentation to support that your quality control operations are approving and releasing from quarantine all components before use in the manufacture of a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control operations failed to approve for release, or reject, any packaged and labeled dietary supplements for distribution, as required by 21 CFR 111.127(h). Specifically, your distribution records show that your quality control signed and released Chromium Picolinate Lot 40223 on 7\u002F18\u002F2023, after the finished dietary supplement was shipped on 6\u002F19\u002F2023. Your distribution records further show that your quality control signed and released CalComplex Lot 523008 on 8\u002F22\u002F2023, after the finished dietary supplement was shipped on 8\u002F9\u002F2023.\u003Cbr>\n\u003Cbr>\nWe have reviewed your response dated December 7, 2023, in which you state there was confusion and disorganization of the batch records which unintentionally led to unexpected timing gaps between shipping to the client and your formal material release paperwork. You also provided your updated procedure 12-E-01 Testing and Release of Finished Product, training records, and updated disposition records for Chromium Picolinate Lot 40223 and CalComplex Lot 523008. However, you did not provide documentation to support that you are distributing finished dietary supplements only after approval and release by your quality control unit.\u003C\u002Fp>\n\n\u003Cp>6. You failed to prepare and follow master manufacturing records that include written instructions that include specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, and specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.205 and 21 CFR 111.210(h)(1) and (h)(3). Specifically, your manufacturing records for CalComplex, Calcium Pyruvate, and Chromium Picolinate do not include written instructions for manufacturing, packaging, and labeling steps, nor do the records identify those points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you provided revised MMR templates for the CalComplex, Calcium Pyruvate, and Chromium Picolinate. However, we are unable to fully evaluate your proposed corrective actions because you did not provide documentation demonstrating that you have implemented and are following your corrective action in the master manufacturing records for a manufactured batch of CalComplex, Calcium Pyruvate, and Chromium Picolinate.\u003C\u002Fp>\n\n\u003Cp>7. Your batch production record failed to include all information required by 21 CFR 111.260. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include a statement of the actual yield at appropriate phases of the processing, as required by 21 CFR 111.260(f);\u003C\u002Fp>\n\n\u003Cp>b. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include the identity of each component used, as required by 21 CFR 111.260(e). For example, the Master Formula page for Calcium Pyruvate Lot 150822 has the weigh out of each component that totals \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there is a \u003Cstrong>(b)(4)\u003C\u002Fstrong> set of weights \u003Cstrong>(b)(4)\u003C\u002Fstrong> that does not have the identity of the component documented;\u003Cbr>\n\u003Cbr>\nc. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include an actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record, as required by 21 CFR 111.260(k)(2);\u003C\u002Fp>\n\n\u003Cp>d. Batch production records did not include documentation at the time of performance that quality control personnel reviewed the batch production records, as required by 21 CFR 111.260(l)(1). Specifically, for Chromium Picolinate Lot 40223, there was no quality review sign off for labeling and packaging materials. For CalComplex Lot 523008 there was no quality review sign off for labeling materials.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023. Your response includes updated BPRs. However, we are unable to further evaluate your response since it did not include any evidence that you have implemented the proposed corrective actions in executed batch production records.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed product labels collected during the inspection and have determined the Calcium Pyruvate, Chromium Picolinate, and Calcium Complex Formula #3 (CalComplex) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. The Calcium Pyruvate and Chromium Picolinate products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the labels fail to bear a domestic address or domestic phone number through which the responsible person, as described in section 761 of the Act [21 U.S.C. 379aa-1] may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>2. The CalComplex, Calcium Pyruvate, and Chromium Picolinate products are misbranded within the meaning of section 403 (q)(5)(F) of the Act (21 U.S.C. 343(q)(5)(F)) in that the presentation of the nutrition information on the labeling of these products does not comply with 21 CFR 101.36 and 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>a. For the CalComplex product:\u003Cbr>\n&nbsp; i. The presentation of the (b)(2)-dietary ingredients is not in the order as set forth in 21 CFR 101.36(b)(2)(i)(B). For example, the declaration of calcium must appear before the declaration of phosphorus.\u003C\u002Fp>\n\n\u003Cp>b. For your Calcium Pyruvate product:\u003Cbr>\n&nbsp; i. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\u003Cbr>\n&nbsp; ii. The label lists calcium pyruvate which is not the nomenclature specified for calcium in 21 CFR 101.9(c)(8) or 21 CFR 101.36(b)(2). The source ingredient that supplies a dietary ingredient may be identified within the nutrition label in parentheses immediately following or indented beneath the name of a dietary ingredient and preceded by the words \"as\" or \"from\", e.g., \"Calcium (as calcium pyruvate)\". When a source ingredient is not identified within the nutrition label, it shall be listed in an ingredient statement [21 CFR 101.36(d)].\u003Cbr>\n&nbsp; iii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\u003Cbr>\n&nbsp; iv. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\u003C\u002Fp>\n\n\u003Cp>c. For the Chromium Picolinate product:\u003Cbr>\n&nbsp; i. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\u003Cbr>\n&nbsp; ii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\u003Cbr>\n&nbsp; iii. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comments:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>For the CalComplex product, the statement “Allergen Warning” appears before the Contains statement, which is considered intervening material.\u003C\u002Fli>\n\t\u003Cli>We note that the CalComplex product declares “Naticol Marine Collagen.” Naticol’s website at https:\u002F\u002Fwww.naticol.com\u002Fen\u002Fnaticol-en\u002F describes their ingredients as “a range of bioactive and bioavailable marine collagen peptides of natural origin.” If the dietary ingredient used in this product is marine peptides, that ingredient must be declared by its common or usual name.\u003C\u002Fli>\n\t\u003Cli>For the Cal Complex product, “Aquamin™” is not the common or usual name for&nbsp;\u003Cem>Lithothamnion\u003C\u002Fem> spp.\u003C\u002Fli>\n\t\u003Cli>For the Calcium Pyruvate product, the statement “**Daily Value not Established” must bewithin the Supplements Facts label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\nLos Angeles District Office\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>or emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to the Unique Identification Number CMS 672954 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDarla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations- West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nRobert P. Bailly\n\nRecipient Title\n\nActing CEO\n\nWest Coast Laboratories, Inc.\n\n116 E. Alondra Blvd.\n\nGardena, CA 90248-2806\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nJune 12, 2024\n\nWL 672954\n\nDear Mr. Bailly:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 116 E. Alondra Blvd., Gardena, CA from October 3 through October 24, 2023. Based on the inspectional findings we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of the inspection on October 24, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 15, December 1, and December 7, 2023. Your November 15 and December 1, 2023, communications did not address the specific observations. We address your December 7, 2023, response below, where relevant.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility from October 3, 2023, through October 24, 2023, identified serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Calcium Pyruvate, Chromium Picolinate, and CalComplex products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of the CGMP requirements are as follows:\n\n1. You did not conduct at least one appropriate test or examination to verify the identity of a dietary ingredient, prior to its use, as required by 21 CFR 111.75(a)(1)(i), nor did you petition the agency under 21 CFR 111.75(a)(1)(ii) for exemption from such testing.\n\nSpecifically, you did not conduct identity testing for (b)(4) Lot (b)(4), Naticol HPMG Lot (b)(4), and Aquamin F (b)(4) used in the manufacture of CalComplex Lot 523008; you did not conduct identity testing for (b)(4) Lot (b)(4) used in the manufacture of Chromium Picolinate Lot 40223; nor did you conduct identity testing for Calcium Pyruvate Lots (b)(4) or Lot (b)(4) used in the manufacture of Calcium Pyruvate Lot 150822. You also have not petitioned the agency for an exemption for such testing.\n\nWe have reviewed your response dated December 7 ,2023, in which you provided revised raw material specifications for Aquamin F, Calcium Pyruvate, (b)(4), and Naticol HPMG. Each of these documents purports to establish a specification of more than (b)(4) match by FTIR. However, you did not provide test records to support that you are conducting identity testing in accordance with the established identity specifications for each of these components.\n\n2. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically:\n\na. For (b)(4) you do not have specifications to ensure the purity, strength, and composition of the (b)(4) and (b)(4) used in the manufacture of CalComplex.\n\nb. For Naticol HPMG you do not have specifications to ensure the purity, strength, and composition of proteins used in the manufacture of CalComplex.\n\nc. For Aquamin F you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the manufacture of CalComplex.\n\nd. For (b)(4) you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the Chromium Picolinate dietary supplement.\n\ne. For Calcium Pyruvate you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the manufacture of Calcium Pyruvate.\n\nIn addition to establishing these specifications, you must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n\nWe have reviewed your response dated December 7 ,2023, which included revised specifications for the ingredients Calcium Pyruvate, (b)(4); and finished product specifications for Chromium Picolinate, CalComplex, and Calcium Pyruvate. Your revised specifications do not meet the requirements of 21 CFR 111.70(b)(2) in that they do not include appropriate specifications to ensure the purity and composition of Chromium Picolinate, Calcium Pyruvate and CalComplex.\n\n3. Your quality control approved and released for distribution a batch of dietary supplement for which a component in the batch did not meet its identity specification, as required by 21 CFR 111.123(b)(1). Specifically, (b)(4) Analytical\u002FChemical Certificate of Analysis dated 9\u002F23\u002F22 for Calcium Pyruvate Lot (b)(4) includes an out-of-specification result of (b)(4) for Calcium. The specification is (b)(4). The ingredient was used in the manufacture of Calcium Pyruvate Lot 150822 on 9\u002F9\u002F22, which was prior to testing. Your quality control approved and released the batch on 10\u002F21\u002F22.\n\n4. Your quality control operations failed to approve and release all components from quarantine before they are used in the manufacture of a dietary supplement, as required by 21 CFR 111.120(e). Specifically, you used the following components in manufacture before your quality control personnel approved and released them from quarantine:\n\na. You used Aquamin F Lot (b)(4) on 6\u002F28\u002F23 in the manufacture of CalComplex Lot 523008; however, the dietary ingredient was not approved and released from quarantine until 10\u002F10\u002F23.\n\nb. You used Calcium Pyruvate Lot (b)(4) on 9\u002F8\u002F22 in the manufacture of Calcium Pyruvate Lot 150822; however, the dietary ingredient was not approved and released from quarantine until 9\u002F26\u002F22.\n\nWe have reviewed your response dated December 7 ,2023, in which you state you investigated and concluded that personnel turnover and insufficient training was the most probable cause of the component’s documented release timing delay. Additionally, you state CalComplex Lot 523008 and Calcium Pyruvate Lot 150822 met all strength claims. You provided finished product strength test results for CalComplex Lot 523008 and Calcium Pyruvate Lot 150822, updated procedure 12-D-01 (Raw material Component Identity Testing), and staff training records; however, you did not provide documentation to support that your quality control operations are approving and releasing from quarantine all components before use in the manufacture of a dietary supplement.\n\n5. Your quality control operations failed to approve for release, or reject, any packaged and labeled dietary supplements for distribution, as required by 21 CFR 111.127(h). Specifically, your distribution records show that your quality control signed and released Chromium Picolinate Lot 40223 on 7\u002F18\u002F2023, after the finished dietary supplement was shipped on 6\u002F19\u002F2023. Your distribution records further show that your quality control signed and released CalComplex Lot 523008 on 8\u002F22\u002F2023, after the finished dietary supplement was shipped on 8\u002F9\u002F2023.\n\nWe have reviewed your response dated December 7, 2023, in which you state there was confusion and disorganization of the batch records which unintentionally led to unexpected timing gaps between shipping to the client and your formal material release paperwork. You also provided your updated procedure 12-E-01 Testing and Release of Finished Product, training records, and updated disposition records for Chromium Picolinate Lot 40223 and CalComplex Lot 523008. However, you did not provide documentation to support that you are distributing finished dietary supplements only after approval and release by your quality control unit.\n\n6. You failed to prepare and follow master manufacturing records that include written instructions that include specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, and specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.205 and 21 CFR 111.210(h)(1) and (h)(3). Specifically, your manufacturing records for CalComplex, Calcium Pyruvate, and Chromium Picolinate do not include written instructions for manufacturing, packaging, and labeling steps, nor do the records identify those points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement.\n\nWe have reviewed your response dated December 7 ,2023, in which you provided revised MMR templates for the CalComplex, Calcium Pyruvate, and Chromium Picolinate. However, we are unable to fully evaluate your proposed corrective actions because you did not provide documentation demonstrating that you have implemented and are following your corrective action in the master manufacturing records for a manufactured batch of CalComplex, Calcium Pyruvate, and Chromium Picolinate.\n\n7. Your batch production record failed to include all information required by 21 CFR 111.260. Specifically:\n\na. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include a statement of the actual yield at appropriate phases of the processing, as required by 21 CFR 111.260(f);\n\nb. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include the identity of each component used, as required by 21 CFR 111.260(e). For example, the Master Formula page for Calcium Pyruvate Lot 150822 has the weigh out of each component that totals (b)(4); however, there is a (b)(4) set of weights (b)(4) that does not have the identity of the component documented;\n\nc. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include an actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record, as required by 21 CFR 111.260(k)(2);\n\nd. Batch production records did not include documentation at the time of performance that quality control personnel reviewed the batch production records, as required by 21 CFR 111.260(l)(1). Specifically, for Chromium Picolinate Lot 40223, there was no quality review sign off for labeling and packaging materials. For CalComplex Lot 523008 there was no quality review sign off for labeling materials.\n\nWe have reviewed your response dated December 7 ,2023. Your response includes updated BPRs. However, we are unable to further evaluate your response since it did not include any evidence that you have implemented the proposed corrective actions in executed batch production records.\n\nMisbranded Dietary Supplements\n\nIn addition, we reviewed product labels collected during the inspection and have determined the Calcium Pyruvate, Chromium Picolinate, and Calcium Complex Formula #3 (CalComplex) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. The Calcium Pyruvate and Chromium Picolinate products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the labels fail to bear a domestic address or domestic phone number through which the responsible person, as described in section 761 of the Act [21 U.S.C. 379aa-1] may receive a report of a serious adverse event with such dietary supplement.\n\n2. The CalComplex, Calcium Pyruvate, and Chromium Picolinate products are misbranded within the meaning of section 403 (q)(5)(F) of the Act (21 U.S.C. 343(q)(5)(F)) in that the presentation of the nutrition information on the labeling of these products does not comply with 21 CFR 101.36 and 101.9. For example:\n\na. For the CalComplex product:\n\ni. The presentation of the (b)(2)-dietary ingredients is not in the order as set forth in 21 CFR 101.36(b)(2)(i)(B). For example, the declaration of calcium must appear before the declaration of phosphorus.\n\nb. For your Calcium Pyruvate product:\n\ni. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\n\nii. The label lists calcium pyruvate which is not the nomenclature specified for calcium in 21 CFR 101.9(c)(8) or 21 CFR 101.36(b)(2). The source ingredient that supplies a dietary ingredient may be identified within the nutrition label in parentheses immediately following or indented beneath the name of a dietary ingredient and preceded by the words \"as\" or \"from\", e.g., \"Calcium (as calcium pyruvate)\". When a source ingredient is not identified within the nutrition label, it shall be listed in an ingredient statement [21 CFR 101.36(d)].\n\niii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\n\niv. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\n\nc. For the Chromium Picolinate product:\n\ni. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\n\nii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\n\niii. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also have the following comments:\n\nFor the CalComplex product, the statement “Allergen Warning” appears before the Contains statement, which is considered intervening material.\n\nWe note that the CalComplex product declares “Naticol Marine Collagen.” Naticol’s website at https:\u002F\u002Fwww.naticol.com\u002Fen\u002Fnaticol-en\u002F describes their ingredients as “a range of bioactive and bioavailable marine collagen peptides of natural origin.” If the dietary ingredient used in this product is marine peptides, that ingredient must be declared by its common or usual name.\n\nFor the Cal Complex product, “Aquamin™” is not the common or usual name for Lithothamnion spp.\n\nFor the Calcium Pyruvate product, the statement “**Daily Value not Established” must bewithin the Supplements Facts label.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to:\n\nSergio Chavez, Director Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\nLos Angeles District Office\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nor emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\n\nRefer to the Unique Identification Number CMS 672954 when replying.\n\nIf you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations- West Division 5","West Coast Laboratories, Inc.","west-coast-laboratories-inc-672954-06122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-laboratories-inc-672954-06122024","2026-10-26T08:10:31.108477+00:00","2024-07-23","672954","Dietary Supplements","Robert P. Bailly","2026-08-19T23:57:04.117+00:00",{"id":114,"raw":115,"subject":120,"body_html":121,"body_text":122,"firm_name":123,"letter_id":124,"created_at":125,"fei_number":19,"letter_url":126,"updated_at":127,"action_type":22,"case_status":23,"posted_date":128,"marcs_cms_no":129,"product_type":130,"closeout_date":19,"issuing_office":119,"recipient_name":131,"body_fetched_at":132,"delivery_method":133,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},6168,[116,117,118,119,120,13,13,13],"\u003Ctime datetime=\"2022-07-26T13:20:00Z\">07\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-30T04:00:00Z\">06\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbi-coastal-pharma-international-628196-06302022\">Bi-Coastal Pharma International\u003C\u002Fa>","Office of Pharmaceutical Quality Operations Division I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ralph Massa, Jr.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bi-Coastal Pharma International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1161 Broad St Ste 216\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shrewsbury\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07702-4362\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations Division I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 628196\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 30, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Massa:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bi-Coastal Pharma International, FEI 3013263547, located at 1161 Broad St Ste 216, Shrewsbury, New Jersey, from December 15, 2021, to January 14, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 2, 2022, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192. (21 CFR 211.198(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate a complaint. On June 2, 2020, FDA notified your firm of a complaint that reported an adverse reaction after taking Chlordiazepoxide Hydrochloride (HCl) and Clidinium Bromide (Br), 5 mg\u002F2.5 mg, distributed by your firm. This notification also included the complainant’s contact information. During this inspection we observed there was no investigation initiated to evaluate the manufacturing and packaging of Chlordiazepoxide HCl and Clidinium Br in accordance with your established procedure. On July 6, 2020, you responded to FDA you reviewed “all” certificates of analysis provided by your contract manufacturing organization (CMO) and concluded results were consistent with all previously released batches. This drug product was manufactured by your CMO \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA issued a Warning Letter\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which specifically noted a violation related to potential for mix-ups of various drug products including Chlordiazepoxide HCl and Clidinium Br. However, at the time of receiving the complaint, you did not attempt to obtain samples of the drug or additional information from the complainant.\u003C\u002Fp>\n\n\u003Cp>You stated during the inspection that your CMO was no longer in business, and you were unable to share the complaint with the CMO for further investigation. However, as the product owner, you are ultimately responsible for ensuring adequate control over outsourced activities, including quality oversight of the drug products you distribute.\u003C\u002Fp>\n\n\u003Cp>In your response, you explained you will revise your process for handling complaints. Your response is inadequate. You failed to provide evidence of your investigation into the product quality impact of this complaint, including the two batches of Chlordiazepoxide HCl and Clidinium Br, 5 mg\u002F2.5 mg manufactured since 2018. In addition, your response lacks systemic evaluation of complaint investigations to ensure adequate and sustainable corrections and corrective actions are implemented in a timely manner.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out of specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A retrospective review of all records that may constitute a complaint for U.S. products and provide a report summarizing the findings of this review including any actions that your firm may take based on the review.\u003Cbr>\n• An evaluation of your existing processes and procedures that define, establish, and document quality and manufacturing related controls to ensure CGMP responsibilities will be carried out if a CMO is no longer in business. Provide a summary of this evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish adequate written responsibilities and procedures for reviewing manufacturing operations performed by your CMOs. You also failed to follow your established procedures, and review each batch produced for you to determine appropriate disposition. For example:\u003C\u002Fp>\n\n\u003Cp>A. Lack of Quality Unit (QU) oversight over CMO\u003C\u002Fp>\n\n\u003Cp>• You use a CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture Hydroquinone USP 4% Skin Bleaching Cream. Your CMO released batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> to you on November 16, 2020. You distributed this batch to numerous customers. During the inspection you were unable to provide adequate stability data for your batch and formulation.\u003C\u002Fp>\n\n\u003Cp>• You use a CMO, \u003Cstrong>(b)(4)\u003C\u002Fstrong> to manufacture the following products:\u003Cbr>\n&nbsp; o Hydroquinone USP 4% Skin Bleaching Cream\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 10% &amp; Sulfur 5% Cleanser\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 10% and Sulfur 2% Cleanser\u003Cbr>\n&nbsp; o Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser\u003Cbr>\n&nbsp; o Selenium Sulfide 2.25% Shampoo\u003C\u002Fp>\n\n\u003Cp>Your manufacturing and supply agreement requires \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure products manufactured on your behalf will not be in violation of FDA regulations. However, this document lacks specificity in defining responsibilities for documenting and performing various oversight activities related to reviewing OOS results, deviations, complaints, and change controls.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. We acknowledge receipt of your CMO’s annual review for Hydroquinone 4% Cream. However, the review does not provide stability characteristics representative of this batch over its shelf life. In addition, you state you will establish written responsibilities for managing your CMOs. However, you have not provided details of your interim controls or an evaluation of the adequacy of your existing agreements with each of your CMOs.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective evaluation of all drug product batches currently in distribution to ensure regulatory responsibilities are adequately delineated between your firm and your CMO to ensure compliance. Provide a summary of this evaluation.\u003Cbr>\n• A summary of your program for qualifying and overseeing CMOs that perform CGMP activities on your behalf. This summary should document the roles and responsibilities of each packager, labeler, distributor, contract manufacturer, contract testing laboratory, or other organization performing activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\u003C\u002Fp>\n\n\u003Cp>B. Failure to follow procedures and lack of written responsibilities\u003C\u002Fp>\n\n\u003Cp>• You failed to follow your established procedure for batch record review and release. During the inspection, you stated you do not receive or verify executed batch records unless requested by FDA during inspections. This is despite a requirement in your procedure that states you will review and verify executed batch records for completeness prior to drug product release. Numerous batches of various drug products have been distributed since December 2019 without your firm receiving or verifying executed batch records.\u003C\u002Fp>\n\n\u003Cp>In addition, after verification of the executed batch record, your procedure requires signatures for the “Reviewed by” space and the “Reviewed and Released by” space in your Certificate of Release. However, our inspection found that Hydroquinone Gel 4% bulk lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong> was released for distribution though the “Reviewed by” space was not signed.\u003Cbr>\n\u003Cbr>\n• Your training procedure states a QU representative will counter sign and date employee training forms, confirming that the employee is appropriately trained on the procedures. However, QU representative signatures were missing on 2020 and 2021 employee training records for various individuals, including QU staff who continued to perform quality duties.\u003C\u002Fp>\n\n\u003Cp>Establishing and following adequate written procedures is essential for the proper functioning of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You failed to provide an investigation into the impact of inadequate batch review and release practices on batches that have been released and remain on the market within their expiry period.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n• A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to ensure that each person responsible for supervising the manufacture, processing, packing, or holding of a drug product has the education, training or experience, or any combination thereof, to perform assigned functions in such a manner as to provide assurance that the drug product has the safety, identity, strength, quality, and purity that it purports or is represented to possess (21 CFR 211.25(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure personnel with oversight of quality related functions have the appropriate combination of training, education, and experience to perform the job adequately. For example, your QA manager:\u003C\u002Fp>\n\n\u003Cp>• Does not have previous experience or educational training in quality assurance, the pharmaceutical industry, or the sciences. Nonetheless, he is responsible for overseeing CMOs, certificates of analysis, and batch release; and\u003Cbr>\n• Was unaware of CGMP stability testing and process validation requirements for drug products manufactured by CMOs on your behalf.\u003C\u002Fp>\n\n\u003Cp>Adequate training and personnel qualifications are essential to ensure proper performance of job functions by your employees, including those responsible for oversight and management of the quality system.\u003C\u002Fp>\n\n\u003Cp>In your response you stated your firm’s “Vice President &amp; General Manager” will help ensure proper adherence to procedures while you seek to hire a new quality assurance manager. This response is inadequate. You failed to provide evidence showing this individual is qualified to provide oversight of CGMP activities. In addition, you have not provided details as to how you will ensure the new quality assurance manager will have the appropriate combination of training, education, and experience to perform the job adequately.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and CAPA for your training program, including practices, records, staff competencies, and effectiveness throughout your operations. Specific gaps should be identified for remediation after assessing the capability of your program to ensure:\u003Cbr>\n&nbsp; o Qualified individuals perform training\u003Cbr>\n&nbsp; o Provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed\u003Cbr>\n• A summary of your current training program.\u003Cbr>\n• Your plan to improve oversight of your training program.\u003Cbr>\n• An assessment of the impact of the lack of appropriate training on marketed drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at h\u003Ca>ttps:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #628196 and include FEI number 3013263547.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officers, CAPT Liatte Closs (Liatte.Closs@fda.hhs.gov) and Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations\u003Cbr>\nDivision I\u002FNew Jersey District\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fandapharm-llc-566492-02282019\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nElectronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Ralph Massa, Jr.\n\nRecipient Title\n\nPresident and CEO\n\nBi-Coastal Pharma International\n\n1161 Broad St Ste 216\n\nShrewsbury, NJ 07702-4362\n\nUnited States\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations Division I\n\nUnited States\n\nWarning Letter 628196\n\nJune 30, 2022\n\nDear Mr. Massa:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Bi-Coastal Pharma International, FEI 3013263547, located at 1161 Broad St Ste 216, Shrewsbury, New Jersey, from December 15, 2021, to January 14, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 2, 2022, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures describing the handling of all written and oral complaints regarding a drug product, including provisions for review by the quality control unit of any complaint involving the possible failure of a drug product to meet any of its specifications and, for such drug products, a determination as to the need for an investigation in accordance with 21 CFR 211.192. (21 CFR 211.198(a)).\n\nYou failed to adequately investigate a complaint. On June 2, 2020, FDA notified your firm of a complaint that reported an adverse reaction after taking Chlordiazepoxide Hydrochloride (HCl) and Clidinium Bromide (Br), 5 mg\u002F2.5 mg, distributed by your firm. This notification also included the complainant’s contact information. During this inspection we observed there was no investigation initiated to evaluate the manufacturing and packaging of Chlordiazepoxide HCl and Clidinium Br in accordance with your established procedure. On July 6, 2020, you responded to FDA you reviewed “all” certificates of analysis provided by your contract manufacturing organization (CMO) and concluded results were consistent with all previously released batches. This drug product was manufactured by your CMO (b)(4), located in (b)(4). FDA issued a Warning Letter1 to (b)(4), on (b)(4), which specifically noted a violation related to potential for mix-ups of various drug products including Chlordiazepoxide HCl and Clidinium Br. However, at the time of receiving the complaint, you did not attempt to obtain samples of the drug or additional information from the complainant.\n\nYou stated during the inspection that your CMO was no longer in business, and you were unable to share the complaint with the CMO for further investigation. However, as the product owner, you are ultimately responsible for ensuring adequate control over outsourced activities, including quality oversight of the drug products you distribute.\n\nIn your response, you explained you will revise your process for handling complaints. Your response is inadequate. You failed to provide evidence of your investigation into the product quality impact of this complaint, including the two batches of Chlordiazepoxide HCl and Clidinium Br, 5 mg\u002F2.5 mg manufactured since 2018. In addition, your response lacks systemic evaluation of complaint investigations to ensure adequate and sustainable corrections and corrective actions are implemented in a timely manner.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out of specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A retrospective review of all records that may constitute a complaint for U.S. products and provide a report summarizing the findings of this review including any actions that your firm may take based on the review.\n\n• An evaluation of your existing processes and procedures that define, establish, and document quality and manufacturing related controls to ensure CGMP responsibilities will be carried out if a CMO is no longer in business. Provide a summary of this evaluation.\n\n2. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality control unit are not in writing and fully followed (21 CFR 211.22(a) and (d)).\n\nYou failed to establish adequate written responsibilities and procedures for reviewing manufacturing operations performed by your CMOs. You also failed to follow your established procedures, and review each batch produced for you to determine appropriate disposition. For example:\n\nA. Lack of Quality Unit (QU) oversight over CMO\n\n• You use a CMO, (b)(4), to manufacture Hydroquinone USP 4% Skin Bleaching Cream. Your CMO released batch (b)(4) to you on November 16, 2020. You distributed this batch to numerous customers. During the inspection you were unable to provide adequate stability data for your batch and formulation.\n\n• You use a CMO, (b)(4) to manufacture the following products:\n\no Hydroquinone USP 4% Skin Bleaching Cream\n\no Sodium Sulfacetamide 10% & Sulfur 5% Cleanser\n\no Sodium Sulfacetamide 10% and Sulfur 2% Cleanser\n\no Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser\n\no Selenium Sulfide 2.25% Shampoo\n\nYour manufacturing and supply agreement requires (b)(4) to ensure products manufactured on your behalf will not be in violation of FDA regulations. However, this document lacks specificity in defining responsibilities for documenting and performing various oversight activities related to reviewing OOS results, deviations, complaints, and change controls.\n\nYour response is inadequate. We acknowledge receipt of your CMO’s annual review for Hydroquinone 4% Cream. However, the review does not provide stability characteristics representative of this batch over its shelf life. In addition, you state you will establish written responsibilities for managing your CMOs. However, you have not provided details of your interim controls or an evaluation of the adequacy of your existing agreements with each of your CMOs.\n\nIn response to this letter, provide:\n\n• A retrospective evaluation of all drug product batches currently in distribution to ensure regulatory responsibilities are adequately delineated between your firm and your CMO to ensure compliance. Provide a summary of this evaluation.\n\n• A summary of your program for qualifying and overseeing CMOs that perform CGMP activities on your behalf. This summary should document the roles and responsibilities of each packager, labeler, distributor, contract manufacturer, contract testing laboratory, or other organization performing activities related to your drug product. Include names, addresses, FDA registration information, and a description of services provided.\n\nB. Failure to follow procedures and lack of written responsibilities\n\n• You failed to follow your established procedure for batch record review and release. During the inspection, you stated you do not receive or verify executed batch records unless requested by FDA during inspections. This is despite a requirement in your procedure that states you will review and verify executed batch records for completeness prior to drug product release. Numerous batches of various drug products have been distributed since December 2019 without your firm receiving or verifying executed batch records.\n\nIn addition, after verification of the executed batch record, your procedure requires signatures for the “Reviewed by” space and the “Reviewed and Released by” space in your Certificate of Release. However, our inspection found that Hydroquinone Gel 4% bulk lot number (b)(4) was released for distribution though the “Reviewed by” space was not signed.\n\n• Your training procedure states a QU representative will counter sign and date employee training forms, confirming that the employee is appropriately trained on the procedures. However, QU representative signatures were missing on 2020 and 2021 employee training records for various individuals, including QU staff who continued to perform quality duties.\n\nEstablishing and following adequate written procedures is essential for the proper functioning of your manufacturing operations.\n\nYour response is inadequate. You failed to provide an investigation into the impact of inadequate batch review and release practices on batches that have been released and remain on the market within their expiry period.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\n• A complete and final review of each batch and its related information before the QU disposition decision\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n3. Your firm failed to ensure that each person responsible for supervising the manufacture, processing, packing, or holding of a drug product has the education, training or experience, or any combination thereof, to perform assigned functions in such a manner as to provide assurance that the drug product has the safety, identity, strength, quality, and purity that it purports or is represented to possess (21 CFR 211.25(b)).\n\nYou failed to ensure personnel with oversight of quality related functions have the appropriate combination of training, education, and experience to perform the job adequately. For example, your QA manager:\n\n• Does not have previous experience or educational training in quality assurance, the pharmaceutical industry, or the sciences. Nonetheless, he is responsible for overseeing CMOs, certificates of analysis, and batch release; and\n\n• Was unaware of CGMP stability testing and process validation requirements for drug products manufactured by CMOs on your behalf.\n\nAdequate training and personnel qualifications are essential to ensure proper performance of job functions by your employees, including those responsible for oversight and management of the quality system.\n\nIn your response you stated your firm’s “Vice President & General Manager” will help ensure proper adherence to procedures while you seek to hire a new quality assurance manager. This response is inadequate. You failed to provide evidence showing this individual is qualified to provide oversight of CGMP activities. In addition, you have not provided details as to how you will ensure the new quality assurance manager will have the appropriate combination of training, education, and experience to perform the job adequately.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and CAPA for your training program, including practices, records, staff competencies, and effectiveness throughout your operations. Specific gaps should be identified for remediation after assessing the capability of your program to ensure:\n\no Qualified individuals perform training\n\no Provisions are implemented for evaluating staff comprehension, training effectiveness, and ensuring appropriate modifications where needed\n\n• A summary of your current training program.\n\n• Your plan to improve oversight of your training program.\n\n• An assessment of the impact of the lack of appropriate training on marketed drug products.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nUse of Contract Manufacturers\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that the FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter #628196 and include FEI number 3013263547.\n\nIf you have questions regarding the content of this letter, please contact us through ORAPHARM1_RESPONSES@fda.hhs.gov, and “cc” Compliance Officers, CAPT Liatte Closs (Liatte.Closs@fda.hhs.gov) and Nancy Scheraga (Nancy.Scheraga@fda.hhs.gov).\n\nSincerely,\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations\n\nDivision I\u002FNew Jersey District\n\n______________________\n\n1 https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fandapharm-llc-566492-02282019","Bi-Coastal Pharma International","bi-coastal-pharma-international-628196-06302022","2026-08-19T04:06:54.551565+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbi-coastal-pharma-international-628196-06302022","2026-10-26T08:08:04.263092+00:00","2022-07-26","628196","Drugs","Mr. Ralph Massa, Jr.","2026-08-20T01:43:38.828+00:00","Electronic Mail","2022-06-30",{"id":136,"raw":137,"subject":142,"body_html":143,"body_text":144,"firm_name":145,"letter_id":146,"created_at":147,"fei_number":19,"letter_url":148,"updated_at":149,"action_type":22,"case_status":23,"posted_date":150,"marcs_cms_no":151,"product_type":152,"closeout_date":19,"issuing_office":141,"recipient_name":19,"body_fetched_at":153,"delivery_method":154,"recipient_title":19,"reference_number":19,"action_taken_date":155,"medical_device_id":19,"response_letter_date":19},2015,[138,139,140,141,142,13,13,13],"\u003Ctime datetime=\"2023-07-05T14:00:00Z\">07\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-29T04:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexclusive-hemp-farmsoshiptcom-648877-06292023\">Exclusive Hemp Farms\u002FOshipt.com\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Interstate Commerce\u002FFood\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Exclusive Hemp Farms\u002FOshipt.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>355 Maycock Road Suite 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gilroy\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95050-7025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 648877\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Etienne:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.exclusivehempfarms.com and www.oshipt.com in February 2023 and June 2023, respectively, and have determined that you take orders for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). Customers place orders for these products on Oshipt.com and receive the orders from Exclusive Hemp Farms (EHF). FDA has determined that your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003Cbr>\n\u003Cbr>\nFDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned that your products are in forms (e.g., candy, chips, and beverages) that are appealing to children, that mimic well-known snack food brands by using similar brand names, logos, or pictures on packaging, and that consumers may confuse with traditional foods. Therefore, with these products there is a risk of unintended consumption of the Delta-8 THC ingredient by consumers. In June 2022, FDA warned consumers about the accidental ingestion by children of food products containing THC.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> As noted in the warning, the agency received over 125 adverse event reports from January 1, 2021, through May 31, 2022, related to children and adults who consumed edible products containing THC. Ten of the reports specifically mention the edible product to be a copycat of popular foods. Your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated may be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated products are foods to which Delta-8 THC has been added. Furthermore, your Oreo Stoneo – Medicated 500mg is labeled with a Nutrition Facts panel which is more likely to be confused for a genuine food or snack product.\u003C\u002Fp>\n\n\u003Cp>As defined in section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act (21 U.S.C. 348(a)) and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in conventional food does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated\u003Cbr>\n\u003Cbr>\nCheddar Snack Crackers 600mg – Medicated products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of FDA’s concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 648877” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unfair or Deceptive Marketing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, the FTC has reviewed your online marketing of Delta-8 THC products. Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. This prohibition includes practices that present unwarranted health or safety risks. Commission Policy Statement on Unfairness, 104 F.T.C. 1070, 1071 (1984) (appended to \u003Cem>Int’l Harvester Co\u003C\u002Fem>., 104 F.T.C. 949 (1984)); \u003Cem>see also Philip Morris, Inc\u003C\u002Fem>., 82 F.T.C. 16 (1973) (alleging that distribution of sample razor blades without protective packaging in home-delivered newspapers was a health and safety hazard, particularly to young children, that violated Section 5). Preventing practices that present unwarranted health and safety risks, particularly to children, is one of the Commission’s highest priorities. FTC Strategic Plan for Fiscal Years 2022-2026 at 5.\u003C\u002Fp>\n\n\u003Cp>As noted above, you have marketed various Delta-8 THC products with an appearance and form similar to conventional foods and candies often consumed by children. For example, you have advertised Oreo Stoneo – Medicated 500mg in packaging resembling that for Nabisco Oreo Double Stuf chocolate cookies, using the same blue background, a red triangle in the upper lefthand corner reading “DABISCO” in the style of the Nabisco logo, and a depiction of a crème-filled chocolate sandwich cookie with a splash of milk. Also, you have marketed Medicated Cheddar Snack Crackers 600mg in packaging using the Cheez-It logo including a depiction of what appear to be Cheez-It crackers. Imitating non-THC-containing food products often consumed by children through the use of advertising or labeling is misleading. FTC Policy\u003C\u002Fp>\n\n\u003Cp>Statement on Deception, 103 F.T.C. 174, 176 n.9 (1984) (appended to \u003Cem>Cliffdale Assocs., Inc\u003C\u002Fem>., 103 F.T.C. 110 (1984)) (the nature, appearance, or intended use of a product may create an impression in the mind of the consumer, and it is deceptive if this impression is false and not corrected by the seller); 15 U.S.C. §§ 52, 55(a)(1) (under Section 12 of the FTC Act, which prohibits false advertisements for foods and drugs, the Commission must consider any consequences that may result from the use of the product under customary or usual conditions).\u003C\u002Fp>\n\n\u003Cp>Children are at particular risk for mistakenly ingesting edible THC products imitating traditional foods because they are more likely to focus on similarities of product appearance and packaging, and less likely to notice or be able to comprehend labeling text. Ingesting edible cannabis products can result in serious health consequences in children.3 Given the significant number of adverse events reported in connection with ingestion of edible products containing THC, advertising and packaging your Delta-8 THC products in a manner that is likely to be particularly appealing to young children could present an unwarranted risk to health and safety.\u003C\u002Fp>\n\n\u003Cp>You must immediately cease marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to be appealing to young children. The FTC also strongly urges you to review all of your marketing and product packaging for similar edible THC products, and to take swift and appropriate steps to protect consumers, especially young children.\u003C\u002Fp>\n\n\u003Cp>With regard to the FTC-related issues described in this letter, please notify Christine DeLorme, attorney with the FTC’s Division of Advertising Practices, via electronic mail at cdelorme@ftc.gov with 15 working days of receipt of this letter of the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Ms. DeLorme at (202) 326-2095.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC (June 16, 2022) https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Falerts-advisories-safety-information\u002Ffda-warns-consumers-about-accidental-ingestion-children-food-products-containing-thc\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See, e.g\u003C\u002Fem>., Marit Tweet et al.,\u003Cem> Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021\u003C\u002Fem>, Pediatrics 2023;151(2): e2022057761.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nExclusive Hemp Farms\u002FOshipt.com\n\n355 Maycock Road Suite 8\n\nGilroy, CA 95050-7025\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 648877\n\nDear Ms. Etienne:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC) reviewed your websites at the Internet addresses www.exclusivehempfarms.com and www.oshipt.com in February 2023 and June 2023, respectively, and have determined that you take orders for various human products, which you represent as containing Delta-8 tetrahydrocannabinol (THC). Customers place orders for these products on Oshipt.com and receive the orders from Exclusive Hemp Farms (EHF). FDA has determined that your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nFDA has observed a proliferation of products containing the cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\n\nFDA is particularly concerned that your products are in forms (e.g., candy, chips, and beverages) that are appealing to children, that mimic well-known snack food brands by using similar brand names, logos, or pictures on packaging, and that consumers may confuse with traditional foods. Therefore, with these products there is a risk of unintended consumption of the Delta-8 THC ingredient by consumers. In June 2022, FDA warned consumers about the accidental ingestion by children of food products containing THC.1 As noted in the warning, the agency received over 125 adverse event reports from January 1, 2021, through May 31, 2022, related to children and adults who consumed edible products containing THC. Ten of the reports specifically mention the edible product to be a copycat of popular foods. Your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated may be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children.\n\nAdulterated Human Foods\n\nAccording to your product labeling, your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated Cheddar Snack Crackers 600mg – Medicated products are foods to which Delta-8 THC has been added. Furthermore, your Oreo Stoneo – Medicated 500mg is labeled with a Nutrition Facts panel which is more likely to be confused for a genuine food or snack product.\n\nAs defined in section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the term “food additive” refers to any substance the intended use of which results in it becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.2\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act (21 U.S.C. 348(a)) and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in conventional food does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your Oreo Stoneo – Medicated 500mg, Cannaa Banana Delta 8 - Rope Candy 600mg - 7 Flavors, Pot Tarts Strawberry 1000mg - Medicated, Tropical Sour Patch - Delta-8 500mg, Trips Ahoy Medicated – Real Chocolate Chip Cookies - 600mg Medicated, Trips Ahoy Medicated – Real Chocolate Chunky Cookies - 600mg Medicated, and Medicated\n\nCheddar Snack Crackers 600mg – Medicated products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of FDA’s concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 648877” in the subject line of your email.\n\nUnfair or Deceptive Marketing\n\nIn addition, the FTC has reviewed your online marketing of Delta-8 THC products. Section 5 of the FTC Act prohibits unfair or deceptive acts or practices in or affecting commerce. This prohibition includes practices that present unwarranted health or safety risks. Commission Policy Statement on Unfairness, 104 F.T.C. 1070, 1071 (1984) (appended to Int’l Harvester Co., 104 F.T.C. 949 (1984)); see also Philip Morris, Inc., 82 F.T.C. 16 (1973) (alleging that distribution of sample razor blades without protective packaging in home-delivered newspapers was a health and safety hazard, particularly to young children, that violated Section 5). Preventing practices that present unwarranted health and safety risks, particularly to children, is one of the Commission’s highest priorities. FTC Strategic Plan for Fiscal Years 2022-2026 at 5.\n\nAs noted above, you have marketed various Delta-8 THC products with an appearance and form similar to conventional foods and candies often consumed by children. For example, you have advertised Oreo Stoneo – Medicated 500mg in packaging resembling that for Nabisco Oreo Double Stuf chocolate cookies, using the same blue background, a red triangle in the upper lefthand corner reading “DABISCO” in the style of the Nabisco logo, and a depiction of a crème-filled chocolate sandwich cookie with a splash of milk. Also, you have marketed Medicated Cheddar Snack Crackers 600mg in packaging using the Cheez-It logo including a depiction of what appear to be Cheez-It crackers. Imitating non-THC-containing food products often consumed by children through the use of advertising or labeling is misleading. FTC Policy\n\nStatement on Deception, 103 F.T.C. 174, 176 n.9 (1984) (appended to Cliffdale Assocs., Inc., 103 F.T.C. 110 (1984)) (the nature, appearance, or intended use of a product may create an impression in the mind of the consumer, and it is deceptive if this impression is false and not corrected by the seller); 15 U.S.C. §§ 52, 55(a)(1) (under Section 12 of the FTC Act, which prohibits false advertisements for foods and drugs, the Commission must consider any consequences that may result from the use of the product under customary or usual conditions).\n\nChildren are at particular risk for mistakenly ingesting edible THC products imitating traditional foods because they are more likely to focus on similarities of product appearance and packaging, and less likely to notice or be able to comprehend labeling text. Ingesting edible cannabis products can result in serious health consequences in children.3 Given the significant number of adverse events reported in connection with ingestion of edible products containing THC, advertising and packaging your Delta-8 THC products in a manner that is likely to be particularly appealing to young children could present an unwarranted risk to health and safety.\n\nYou must immediately cease marketing edible Delta-8 THC products that imitate conventional foods using advertising or packaging that is likely to be appealing to young children. The FTC also strongly urges you to review all of your marketing and product packaging for similar edible THC products, and to take swift and appropriate steps to protect consumers, especially young children.\n\nWith regard to the FTC-related issues described in this letter, please notify Christine DeLorme, attorney with the FTC’s Division of Advertising Practices, via electronic mail at cdelorme@ftc.gov with 15 working days of receipt of this letter of the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Ms. DeLorme at (202) 326-2095.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 FDA Warns Consumers About the Accidental Ingestion by Children of Food Products Containing THC (June 16, 2022) https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Falerts-advisories-safety-information\u002Ffda-warns-consumers-about-accidental-ingestion-children-food-products-containing-thc\n\n2 Under section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\n\n3 See, e.g., Marit Tweet et al., Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021, Pediatrics 2023;151(2): e2022057761.","Exclusive Hemp Farms\u002FOshipt.com","exclusive-hemp-farmsoshiptcom-648877-06292023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fexclusive-hemp-farmsoshiptcom-648877-06292023","2026-10-26T08:08:38.173909+00:00","2023-07-05","648877","Dietary SupplementsFood & Beverages","2026-08-20T00:59:01.717+00:00","Via Overnight Delivery","2023-06-29",{"id":157,"raw":158,"subject":163,"body_html":164,"body_text":165,"firm_name":166,"letter_id":167,"created_at":147,"fei_number":19,"letter_url":168,"updated_at":169,"action_type":22,"case_status":23,"posted_date":170,"marcs_cms_no":171,"product_type":46,"closeout_date":19,"issuing_office":100,"recipient_name":172,"body_fetched_at":173,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":174,"medical_device_id":19,"response_letter_date":19},2246,[159,160,161,162,163,13,13,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-02T04:00:00Z\">11\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgold-coast-distributors-inc-dba-shah-distributors-635805-11022022\">Gold Coast Distributors Inc. dba Shah Distributors\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","CGMP\u002FWarehouse\u002FInsanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sourabh Roy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gold Coast Distributors Inc. dba Shah Distributors\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2325 W. Charter Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Stockton\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95206-1135\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL 635805\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roy:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ambient and frozen warehouse and re-packing facility, located at 2325 W. Charter Way, Stockton, CA 95206, from May 09-27, 2022. During our inspection of your facility, the FDA investigators observed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food rule (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, the FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your firm. In addition, during the inspection, FDA collected filth samples from various areas within your warehouse facility, and the analytical results revealed rodent, insect, or cat filth present all throughout your facility.\u003C\u002Fp>\n\n\u003Cp>Based on inspectional and analytical findings, we determined the food products packaged and\u002For held in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that your products have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. You may find the Act and further information about the CGMP &amp; PC rule through links on FDA’s homepage at \u003Ca>www.fda.gov.\u003C\u002Fa> Further, we have reviewed the Ghee product label that was collected during the inspection and found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your product to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343], as discussed below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Further, we received your written response to the FDA-483, dated June 07, 2022, which described corrective actions taken by your firm and included photographs and pest control service reports. Based on our review of the inspectional finding and the response that your firm provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. You did not take effective measures to exclude pests from your packing and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c). Specifically, rodent, insect, and animal activity was observed throughout your facility including, but not limited to the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Rodent Activity observed:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Dry storage room at \u003Cstrong>(b)(4)\u003C\u002Fstrong> end of warehouse\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, numerous rodent excreta pellets (REPs) and several rodent gnawed cardboard co-mingled cases containing various food products (including spices) were observed on pallets and on the floor up against the north, east, and southwest sides of the room. REPs were on floor, on the ledges of the windows along the north wall, and on shelves in an adjacent room (where labels and equipment were stored) at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, two rodent gnawed cardboard cases, having rodent rub marks, REPs, and nesting material that each contained at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F2 oz. retail bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> paprika spice, were observed on the center pallet against the west wall. One dead rodent was observed in between one of the cases of paprika spice and another case of spice products. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags within each case were rodent gnawed where paprika spilled out and onto other bags within the box. REPs, rodent hairs, and rodent nesting material were observed in each box and on, around, and inside \u003Cstrong>(b)(4)\u003C\u002Fstrong> of paprika.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, one rodent gnawed cardboard case having REPs and rodent rub marks contained at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F4 oz. retail bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cumin Seeds. Inside of the box there were at least 2 rodent gnawed bags, and at least 50 REPs, rodent nesting material, and a dead and decayed rodent all nestled within the bags of cumin seeds. The box was located on a pallet at the southwest corner of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, one cardboard case was observed to contain 10 packs of 6\u002F50g boxes of Shan Seasoning Mix Fish Biryani (mix for Spicy Fish Pilaf). At least 5 boxes had rodent gnaw marks. At least 40 REPs were on and in between boxes of the seasoning. All boxes had rodent rub marks and rodent urine stains that made the labeling of the products mostly illegible. The case was located on a pallet against the west wall of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, at least 2 rodent gnawed holes, rodent rub marks, and at least 30 REPs were observed on 1 cardboard case containing at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F24 oz. bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;brand Wheat Pelted (Whole). Within the case, there were at least 5 bags that had rodent gnaw marks where wheat pellet product had spilled out and onto other bags. REPs and rodent nesting material were in the case and inside the rodent gnawed bags. This case was located on boxes along the southwest corner of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, one rodent gnawed cardboard case was observed to contain at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F4 oz. retail bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Granulated Garlic. Within the box there were at least 2 bags that had rodent gnawed holes along with at least 15 REPs on and in between bags. The case was located on the pallet at the southwest wall of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, one cardboard case located on the floor (along with other cases of food products) at the south wall contained at least 5 rodent gnawed bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tea sweetener and at least 9 rodent gnawed boxes labeled \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand. REPs and rodent nesting material were inside every bag, as well as on and in between every box. Rodent rub marks and rodent urine stains on the boxes made the labeling of most boxes illegible.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, and 17, 2022, one cardboard case was observed with at least three apparent rodent gnaw marks containing approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F6 pack shrink wrapped packages of \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes of Shah brand Punjabi Yakhni Pilau. Within this case, there were at least five boxes that had apparent rodent gnaw marks. And at least 20 REPs and apparent rodent urine staining were observed on at least 16 boxes. The case was located along the south wall of the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a large hole (approximately 2’ x 4”) surrounded by sagging sheet rock with black and brown stains was observed in the ceiling above pallets of packaged food product and paper records at the east end of the room. At least 50 REPs, rodent nesting material (including wads of pink insulation) and apparent rodent hairs were on and within 3 opened boxes of paper records below this hole.\u003C\u002Fli>\n\t\u003Cli>On May 19, 2022, after all food products were removed from the storage room, hundreds of REPs, spilled spice products, fragments of rodent gnawed food packing, and rodent nesting material were on the floor of the room. One dead rodent was on the floor at the north wall near the entrance to the room. Two holes, each 3” x 3” and each containing REPs and rodent nesting material, were observed in the south and west walls. These holes were not observed previously during the inspection due to pallets of boxes of spice products stored next to each other and up against walls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Southwest side of the warehouse\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, at least 200 apparent REPs were observed on a box of incense sticks on the top layer of a pallet containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes. At least 10 REPs were found on a box of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> layer of this pallet. The pallet was located at the north end of the warehouse and immediately adjacent to pallets of spice products, including Shan brand Fish Marsala.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Northwest side of the warehouse\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 23, 2022, three apparent REPs were observed on 40 lb. bags of&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> brand basmati sela rice on a pallet containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags. One bag on this pallet had an apparent rodent gnawed hole approximately 3” x 3” that was surrounded by yellowish stains.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Inside \u003Cstrong>(b)(4)\u003C\u002Fstrong> freezer at the northwest end of warehouse\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 17, 2022, an apparent rodent urine stain, approximately 1\u002F2” x 2”, was observed on the floor below returned food products along the southwest wall. Within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> freezer, pallets of boxes of food products were stored up against walls and immediately adjacent to each other within the aisles of the pallet racks. There were no aisles in between the pallets and the racks, making the center and the entire north wall inaccessible for a visual inspection.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Southeast end of the warehouse\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, one dead rodent was found in tin cat #23 located at the entrance to the warehouse from the administrative offices at the southeast side.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Insect activity observed:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 12, 2022, live and dead insects in winged, crawling and larvae forms as well as moth webbing were observed on every bag of every layer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets each containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F55 lb. bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (split chickpeas). Insect bored holes were observed in at least 4 bags of each pallet. \u003Cstrong>(b)(4)\u003C\u002Fstrong> product below the bored holes appeared clumped with insect eggs and had crawling insects. These pallets were located on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of pallet \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, live and dead insects in winged, crawling and larvae forms were observed on and inside several opened bags of products including cashews, cumin spice, curry spice, fennel, bay leaves, legumes, and cinnamon that were in a pile with other food products on the floor of the repack room located at the south end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 23, 2022, an opened, unlabeled cardboard case (3’ x 3’) containing yellow legumes had live and dead insects on the legumes and on the plastic wrap that lightly covered the box. This box was located near the entrance to the repack room at the south end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, live and dead insects in flying, crawling, and larvae forms were observed on and in between bags of expired Swarna brand whole wheat flour that were on \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets each containing at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F20 lb. bags. Live and dead flying and crawling insects were observed on and in between the bags and shrink wrap of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets. Two opened bags contained at least 6 winged and crawling insects. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets were located next to pallets of boxes and bags of food product including basmati rice at the north end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 23, 2022, at least 5 dead insects were observed around a 1” x 1” hole in a 25 lb. bag of expired \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand desiccated coconut. The bag was on a pallet of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F25 lb. soiled and dirty bags located between roll up doors 2 and 3 at the east end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, pallets of boxes of food products (including soup mixes and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand drinks) returned from a customer that were observed damaged, dirty, and showing insect activity were commingled with food products intended for sale along the east and west sides of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, dead and\u002For live cockroaches were found in 18 tin cats staged round the inside perimeter of the warehouse. These included 34 live and dead cockroaches in tin cat #4 located between roll up doors 2 and 3 along the east wall; 30 live and dead cockroaches in tin cat #10 at the north wall; 70 live and dead cockroaches in tin cat# 14 at the west wall; and 49 live and dead cockroaches in tin cat #17 at the southwest wall.\u003C\u002Fli>\n\t\u003Cli>On May 16, 2022, live and dead insects in winged, crawling and larvae forms were found on and around boxes and bags of various food products (including basmati rice) located at each pallet rack within the center of the warehouse.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Animal activity observed:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, piles of cat feces were observed on the floor at the north wall, northeast corner, south wall, southeast corner, west wall, and northwest corner of the warehouse. A pile of cat feces was also observed under pallet \u003Cstrong>(b)(4)\u003C\u002Fstrong> beneath boxes of soft drink beverage products.\u003C\u002Fli>\n\t\u003Cli>On May 17, 2022, at least 4 empty bags of dried cat food were observed in the room above the repack room. Animal paw prints were observed on dusty boxes (holding food products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> instant mix) located at the north, south, and southwest ends of the warehouse. Animal paw prints were observed on boxes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand cookies located on a pallet near the entrance to the dry storage room.\u003C\u002Fli>\n\t\u003Cli>On May 12, 2022, cat urine was identified on 2\u002F55 lb. bags of \u003Cstrong>(b)(4)\u003C\u002Fstrong> (split chickpeas) that were located on layers \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallet containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F55 lb. bags. This pallet was located on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of pallet \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A bag of \u003Cstrong>(b)(4)\u003C\u002Fstrong> product on the top layer was found saturated with cat urine.\u003C\u002Fli>\n\t\u003Cli>On May 18, 2022, at approximately 11:00 AM, one live apparent bat was observed flying in circles and landing in the seam between two concrete slabs and a wooden ceiling joist along the south wall between the dry goods storage room and the west wall of the warehouse.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Structural deficiencies observed:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a gap approximately 2’ x 4” was observed at the upper right side of the closed rollup door #1 at the east end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a hole approximately 3” x 3” was observed at the left side and base of closed roll up door #2 at the east end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a gap approximately 2” x 1” was observed at the center and base of closed roll up door #3 at the east end of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a pedestrian door #10, located at the northeast end of the warehouse, was ajar and held closed with a belt. There was a 1”- 3” gap that spanned the base of the door, and a 1 ½’ x 3” gap along the lower right side of the door.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a gap approximately 1” to 3” was observed at the base of the closed pedestrian door, located at tin cat #12 at the northwest end of the warehouse.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Harborage areas inside the warehouse observed:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, pallets of boxes of Shan brand food products (including pickles and spices) were stored immediately adjacent to each other and up against walls all along the north wall of the warehouse. Tin cats # 6, 8, and 9 placed by the pest control provider along the north wall were either missing or inaccessible.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, pallets of boxes of food products returned from customers that were damaged, dirty, and showing insect or rodent activity were commingled with products slated for sale to customers along the east and west sides of the warehouse.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Pest control records:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to visual observations, our investigators conducted a review of your third-party pest control provider inspection reports which revealed the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Report dated 11\u002F20\u002F2019 showed the technician observed \"Gaps on all exterior doors - All man doors and roll up doors have gaps at the bottom of the entrance allowing insect and rodent presence.\"\u003C\u002Fli>\n\t\u003Cli>Report dated 04\u002F30\u002F2020 showed the technician observed “food product all over the floor that is giving insects and rodents a food source, weeds around the structure, damaged food inside multiple opened containers and pallets of food located on the north and west side of the building, and multiple pallets stored too closely to the north wall of the facility giving rodents and insects harboring areas.\" The technician recommended that the firm \"clean up the property.\"\u003C\u002Fli>\n\t\u003Cli>Report dated 06\u002F05\u002F2020 showed rodent activities and cat activities inside the warehouse. Technician noted no changes to the containers (doors kept open) and improper storage throughout the perimeter wall and exterior of the building as observed on 04\u002F30\u002F2020. Technician also noted \"heavy pigeon activity and droppings\" and that he found a litter of cats inside of the warehouse that were being fed by employees. It was noted that areas were not being cleaned and sanitized as needed and that there was a need to re-evaluate the account to continue to provide their services to this site.\u003C\u002Fli>\n\t\u003Cli>Report from 08\u002F07\u002F2020 showed rodent activity and cat feces throughout the facility. Technician observed and noted a cat sleeping on “expired pallets” and heavy cat droppings on the west side of the building between the cooler and the west side interior walls. Technician noted that there were still pallets and shipping containers with damaged and outdated product being stored outside that needed to be removed.\u003C\u002Fli>\n\t\u003Cli>Reports in 2021 consistently showed rodent activities, cat droppings in the warehouse, pallets with food leading to pest harborage\u002Fattractant, in addition to activities of Oriental and Turkistan roaches, ants, and bats. On 06\u002F14\u002F2021, the technician noted that he \"found a pallet of cornmeal near trap 7 that was infested with stored product pest\" and that \"this pallet should be removed immediately.\" Also, on 08\u002F26\u002F2021, the technician noticed \"Indian meal moth activity that is most likely coming from old, expired product that is sitting in the warehouse.\" On 10\u002F25\u002F2021 and 11\u002F23\u002F2021, the technician noted some of the traps were inaccessible for inspection.\u003C\u002Fli>\n\t\u003Cli>Reports dated 04\u002F22\u002F2022, 03\u002F22\u002F2022, 02\u002F22\u002F2022, and 01\u002F24\u002F2022 showed the technician repeatedly stated: “Gaps on all exterior doors[.] [A]ll pedestrian doorways and roll up doors have gaps at the bottom of the entrance allowing insects and rodent presence. Food product throughout the warehouse[.] [T]here is food product all over the floor that is giving insects and rodents a food source. Damaged food on the north and west side of the building[.] [T]here are multiple shipping containers that are opened with damaged food product[,] and there are multiple pallets that are damaged with food product on it. On the north side of the facility there are multiple pallets that are too close to the structure giving rodents and insects harboring areas.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Samples\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA collected several samples during the inspection (samples 1184925, 1176915, 1182925, 1183037 and 1183038). These samples were submitted to FDA labs for analysis. Results demonstrate that submitted product [including \u003Cstrong>(b)(4)\u003C\u002Fstrong> (split chickpeas) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand Paprika] were contaminated with rodent\u002Fmouse hairs, cat hair and urine, urine stains (on packaging), gnaw marks, REPs as well as various species of larval, pupal, and adult insects. Further, sample 1184925 had evidence of insect penetration and damage to packaging and product as well as urine stains and yeast. The filth samples further demonstrated the presence of rodents and insect activity throughout the facility through the presence of rodent hairs, teeth marks, in pellet morphology and nesting materials as well as confirmation of various species of insects at larval, pupae and adult stages.\u003C\u002Fp>\n\n\u003Cp>Your June 7, 2022, written response indicated that you contracted with a new third-party pest control provider and increased service frequency \u003Cstrong>(b)(4)\u003C\u002Fstrong> a month. In addition, you described a treatment plan to gain control of your facility and remove all pest activity from the interior and exterior. Further, you provided service reports dated 05\u002F26, 05\u002F27, 05\u002F31, and 06\u002F03\u002F2022; however, these reports do not show the frequency for routine service. Also, you did not provide confirmation of other actions promised by your response, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> application over a \u003Cstrong>(b)(4)\u003C\u002Fstrong> period, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> rodent trapping program, and establishment of a bat exclusion program.\u003C\u002Fp>\n\n\u003Cp>In addition, your response indicated that all gaps and holes in doors have been repaired to eliminate pest route of entry. Further, you stated all areas of the facility, including warehouse, dry storage, walk-in freezer and packing room have been cleaned to remove rodent, animal, and insect filth. You also indicated that all affected product (damaged, expired, or containing urine stains or REPs) has been removed and discarded and that pallets have been moved away from walls for accessibility. However, you did not provide documentation to demonstrate repairs were made and the effectiveness of cleaning and pest removal, with the exception of the dry storage room. Further, you did not indicate how you plan to continue to maintain the facility and equipment in a sanitary condition.\u003C\u002Fp>\n\n\u003Cp>2. You failed to properly store equipment, remove litter and waste, and cut weeds and grass that may constitute an attractant, breeding place, or harborage for pests within the immediate vicinity of the plant, as required by 117.20(a)(1). Specifically,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, piles of damaged pallets, pipes, garbage and boxes of food products (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand mango juice drinks and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand mango fruit nectar drinks) were along the north side of the building, by the dumpsters in the parking lot at the east end of the warehouse\u003C\u002Fli>\n\t\u003Cli>On May 12, 17-19, and 23, 2022, at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets of boxes of food product (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand fun snacks rice bites and Shan brand Shoop Instant noodles) were located at the northwest end. Bird feces was on the concrete pavement around the pallets of products.\u003C\u002Fli>\n\t\u003Cli>On May 12, 17-19, and 23, 2022, several piles of broken pallets, unused equipment, and garbage were all along the fence line outside the west end of the firm.\u003C\u002Fli>\n\t\u003Cli>On May 12, 17-19, and 23, 2022, three opened shipping containers, located outside at the west and northwest ends of the warehouse, each contained pallets of dirty and damaged boxes and bags of food products. Some bags and boxes were torn open where food product spilled out on to the floor and outside of the containers. All products within all three containers were haphazardly arranged, immediately adjacent to each other, and up against the sides of the containers. There were no aisles between products that would allow for a visual inspection within any of the containers.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, overgrown weeds spanned along the fence lines at the north and northwest sides of the warehouse.\u003C\u002Fli>\n\t\u003Cli>On May 17, 2022, one live adult cat and 5 kittens were observed on top of a pallet of boxes of Falak brand basmati rice stored in an opened shipping container located outside of the warehouse at the west end.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In addition, on May 12, 2022, the following food products slated for destruction were located outside on your grounds:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets containing boxes of prepackaged drinks were observed stored outside at the northeast wall.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> pallets of boxes of food products (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> Brand fun snacks rice bites and Shan brand Shoop instant noodles) were observed outside at the northwest wall.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> opened shipping containers, \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the northwest wall and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at the west wall, all containing stacks of bags of dirty, dusty food products including legumes and pallets of boxes of food products including basmati rice that were observed immediately next to each other and up against the walls. There were no aisles in between products that would allow for a visual inspection of the containers. You did not start destroying products until May 23, 2022, after CDPH placed your firm under a blanket embargo on May 17, 2022.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Inventory Controller could not provide an estimate as to how long the food slated for destruction had been kept outside. This employee stated that dumpsters were ordered but could not give a time frame as to when they would arrive.\u003C\u002Fp>\n\n\u003Cp>Further, on May 23, 2022, hundreds of apparent REPs were found around all 6 downspouts of the gutter drainage systems outside and along the south wall of the firm. At least 100 apparent REPs were found around the downspout nearest to the visitor’s entrance of the firm. At least 300 apparent REPs were found around the 3rd downspout located at the center of the south wall. Apparent rodents were heard moving about the inside of the piping system that led this downspout.\u003C\u002Fp>\n\n\u003Cp>Your June 7 response stated that all food product and food debris have been discarded from the yard area damaged pallets and materials have been removed, and the grounds have been cleaned to remove pests, litter, trash, spoiled food, and feces. You also indicated that four storage containers have been emptied, cleaned and the product discarded. However, you did not provide documentation to demonstrate that these activities were performed, with the exception of one photograph of the grounds along an unidentified exterior wall. Further, you did not indicate how you plan to continue to maintain your yard in a sanitary condition.\u003C\u002Fp>\n\n\u003Cp>Your written response also described processes established for the management of product slated for destruction. We are not able to fully evaluate the adequacy of this corrective action as you did not provide supporting documentation of its implementation.\u003C\u002Fp>\n\n\u003Cp>3. You did not maintain your plant in a clean and sanitary condition and keep your plant in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Insanitary conditions around your facility demonstrated that sanitation and housekeeping operations were inadequate because your facility provided food sources and pest harborage areas for rodents and other pests which led to widespread product contamination. In addition, inadequate maintenance to parts of the facility allowed for potential pest entry and harborage areas within the facility. Specifically, during the inspection, on May 9, 2022, your firm identified 28 products that may be repacked in a dedicated room at your firm. Among these items are cashews, almonds, cumin powder, cloves, cinnamon, cardamom, and coriander that may be ready-to eat (RTE) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaged by employees within an open environment. The following was observed in your repack room during the inspection:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, buildup of dirt and dust debris on all \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoppers\u002Fproduct filling equipment, scales, and shelves. Food debris, including garbanzo beans, was observed inside, and dusty dirty kidney beans and legumes were observed around the framing of one of the hoppers.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, food products, including bay leaves, fennel seeds, and legumes, were spilled on the floor and on pallets about the room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, and 16-19, 2022, a pile of at least 30\u002F4 oz. retail packages red legumes was on the floor near the entrance to the repack room.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, empty drink containers and food packages were found on shelves and in between bags and boxes of food products.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, opened bags of food products including spices and cashews were observed in a large pile on the floor and up against the south wall. Live and dead insects were observed on and inside of the opened bags of product.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16-19, and 23, 2022, a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink and an adjacent white sink were located at the east end of the room. Both had a build-up of dust and dirt, and a spider web spanned across one basin of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sink. There was no soap, towels, or other means to dry hands at either sink. Your Inventory Controller stated the sinks are not used.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your June 7 response stated the packing room and equipment within have been cleaned and sanitized to remove dust and food debris. You also indicated that all infested product has been removed and discarded. Further, packaging materials have been cleaned. FDA will evaluate the adequacy cleaning and sanitation practices during our next inspection of your facility. Your written response described re-packing and record keeping processes which have been created; however, we are not able to fully evaluate the adequacy of this corrective action as you did not provide supporting documentation of its implementation.\u003C\u002Fp>\n\n\u003Cp>4. You did not provide employees with adequate, readily accessible, and clean toilet facilities to prevent a potential source of contamination of food, food-contact surfaces, or food packaging materials, as required by 21 CFR 117.35(d). Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>On May 9, 12, 16, 17 and 23, 2022, the faucet, located inside the restroom, of the designated handwashing sink was covered with plastic wrap obstructing the use of the sink. There were no soap, towels, or other means to dry hands at this sink.\u003C\u002Fli>\n\t\u003Cli>On May 9, 12, 16, 17 and 23, 2022, within the janitorial area, between the 2 toilets in the room, there was a sink, located in the restroom, that did not have towels or other means to dry hands, and there was no soap but rather a bottle of shampoo next to the faucet.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your June 7 response stated that the employee and office bathrooms have been cleaned and fully stocked with hand soap, paper towels, toilet paper and seat-covers. It also stated that all sinks have been repaired, have hot and cold running water, and are stocked with hand soap and paper towels. Although you provided photographs which show the re-packaging equipment appears to be in sanitary condition, you did not provide photographs or other evidence to demonstrate the condition of the room or sinks. Also, you provided photographs to show a restroom and handwash station were cleaned and stocked appropriately; however, the locations are unknown. Further, you did not indicate how you plan to continue to maintain the facility (including bathrooms) in a sanitary condition. FDA will evaluate the adequacy cleaning and sanitation practices during our next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(w) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(w)] in that the finished product label fails to declare the major food allergen, milk. According to the label, this product is made from “Pure Grade AA Clarified Butter”, which is made from milk. We point out that in your response to the 483 (corrective action plan), there was no mention of correcting the labels.\u003C\u002Fp>\n\n\u003Cp>2. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(a)] because there is a large discrepancy between serving size and servings per container information provided in the Nutrition Facts Label, when compared to the declared net quantity of contents. The net quantity of contents is double what would be calculated for the net quantity based on the information in the Nutrition Facts Label. If the declared serving size of 13g is multiplied by the declared 35 servings per container, the result is 455g, which is about one pound. However, the net quantity of contents for the product is declared as 2lb (32 FL OZ).”\u003C\u002Fp>\n\n\u003Cp>3. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(q) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(q)] because the serving size is not based on the appropriate RACC in accordance with 21 CFR 101.12(b)] and (21 CFR 101.9(b); therefore, all of the values in the nutrition label are incorrect. The label indicates a serving of “1\u002F2 cup” (13 g). The RACC for this product is under the category “Butter, margarine, oil, shortening” and has a reference amount of 1 tbsp and a label statement of “1 tbsp (g) or 1 tbsp(15 mL).” Furthermore, we question whether ½ cup of this product would weigh 13 grams.\u003C\u002Fp>\n\n\u003Cp>4. Your 100% Pure Desi ghee product is misbranded within the meaning of section 403(f) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(f)] because “desi” is a Hindi term; therefore, all required (mandatory) labeling must also be in Hindi, in accordance with section 21 CFR 101.15(c)(2).\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Additionally, we reviewed your Shah Brand ghee product label and offer the following comments:\u003C\u002Fp>\n\n\u003Cp>Ghee is obtained from milk, cream or butter by removing the non-fat milk solids and water, and it typically contains about 99.6% or more milk fat (Codex Standard CXS 280-1973). Ghee is not considered a highly refined oil and is not exempt from major food allergen labeling requirements. Since ghee is prepared from milk, a major food allergen, the label must declare milk as the name of the food source from which the major food allergen is derived.\u003C\u002Fp>\n\n\u003Cp>The amount of non-fat milk solids, including milk proteins, present in ghee can vary depending on manufacturing process. The protein content of the ghee product must be determined for better evaluation of the risk posed by milk proteins remaining in ghee. The protein content in the Shah Brand ghee product is not known. The Nutrition Facts panel of its label indicates a serving size of ½ cup (13 g) and 7g protein, which do not appear to be accurate. A search for nutrient composition of ghee at USDA database indicate 0.28% protein in ghee1. This is equivalent to 0.039 g (39 mg) milk protein in a portion of 14 g (1 tablespoon) ghee. The current science on allergen risk assessment is based on population minimal eliciting dose (ED) distributions, which can be used to determine ED01 and ED05 doses at which 1% and 5% of the allergic population, respectively, can be expected to have allergic reaction\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Remington et al (2020)2\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>estimated ED01 and ED05 for milk protein to be 0.2 mg and 2.4 mg, respectively, which is considerably lower than the milk protein that could be expected in 1 tablespoon of ghee. It can be anticipated that a serving size of 1 tablespoon ghee with 39 mg milk protein can possibly cause allergic reaction in over 25% of milk allergic population based on the ED25 of 32.7 mg for milk protein reported by Houben et al (2020)3\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. We consider the milk proteins remaining in ghee can pose a significant concern of allergic reaction in milk allergic population.\u003C\u002Fp>\n\n\u003Cp>We also note the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is inconsistency within your label’s net quantity of comments statement in that it lists both “NET WT.” and “FL OZ.” 21 CFR 101.7(a).\u003C\u002Fli>\n\t\u003Cli>The information panel is not immediately to the right of the principal display panel, as required by section 21 CFR 101.2.\u003C\u002Fli>\n\t\u003Cli>The street address for your firm is not provided. In accordance with section 21 CFR 101.5(d), the street address is required unless it is shown in a current city directory or telephone directory.\u003C\u002Fli>\n\t\u003Cli>The trans-fat declaration is not expressed in the correct increment as required by section 21 CFR 101.9(c)(2)(ii), and the vitamins and minerals are not declared in accordance with the new Nutrition Facts label (NFL). As you may already know, FDA finalized new requirements for nutrition labeling on May 27, 2016. The new Nutrition Facts label includes updates to the required nutrient declarations and formatting requirements. For more information on the new requirements, please see \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FGuidanceDocumentsRegulatoryInformation\u002FLabelingNutrition\u002Fucm385663.htm\">http:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FGuidanceDocumentsRegulatoryInformation\u002FLabelingNutrition\u002Fucm385663.htm\u003C\u002Fa>.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen (15) working days of the receipt of this letter, as to the specific steps that you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS# 635805 when replying.\u003C\u002Fp>\n\n\u003Cp>If you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> USDA website link FoodData Central (usda.gov).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Remington et al, 2020, Updated population minimal eliciting dose distributions for use in risk assessment of 14 priority food allergens. Food and Chemical Toxicology, 139: 111259.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Houben et al, 2020, Full range of population eliciting dose values for 14 priority allergenic foods and recommendations for use in risk characterization. Food and Chemical Toxicology, 146: 111831.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Sourabh Roy\n\nRecipient Title\n\nCEO\n\nGold Coast Distributors Inc. dba Shah Distributors\n\n2325 W. Charter Way\n\nStockton, CA 95206-1135\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nWL 635805\n\nDear Mr. Roy:\n\nThe United States Food and Drug Administration (FDA) inspected your ambient and frozen warehouse and re-packing facility, located at 2325 W. Charter Way, Stockton, CA 95206, from May 09-27, 2022. During our inspection of your facility, the FDA investigators observed serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food rule (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). At the conclusion of the inspection, the FDA investigators issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your firm. In addition, during the inspection, FDA collected filth samples from various areas within your warehouse facility, and the analytical results revealed rodent, insect, or cat filth present all throughout your facility.\n\nBased on inspectional and analytical findings, we determined the food products packaged and\u002For held in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that your products have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth or whereby they may have been rendered injurious to health. You may find the Act and further information about the CGMP & PC rule through links on FDA’s homepage at www.fda.gov. Further, we have reviewed the Ghee product label that was collected during the inspection and found significant violations of the labeling regulations for foods, 21 CFR Part 101. These violations cause your product to be misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343], as discussed below.\n\n(b)(4). Further, we received your written response to the FDA-483, dated June 07, 2022, which described corrective actions taken by your firm and included photographs and pest control service reports. Based on our review of the inspectional finding and the response that your firm provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B)\n\n1. You did not take effective measures to exclude pests from your packing and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c). Specifically, rodent, insect, and animal activity was observed throughout your facility including, but not limited to the following:\n\nRodent Activity observed:\n\nDry storage room at (b)(4) end of warehouse\n\nOn May 9, 12, 16, and 17, 2022, numerous rodent excreta pellets (REPs) and several rodent gnawed cardboard co-mingled cases containing various food products (including spices) were observed on pallets and on the floor up against the north, east, and southwest sides of the room. REPs were on floor, on the ledges of the windows along the north wall, and on shelves in an adjacent room (where labels and equipment were stored) at the (b)(4) of the room.\n\nOn May 9, 12, 16, and 17, 2022, two rodent gnawed cardboard cases, having rodent rub marks, REPs, and nesting material that each contained at least (b)(4)\u002F2 oz. retail bags of (b)(4) paprika spice, were observed on the center pallet against the west wall. One dead rodent was observed in between one of the cases of paprika spice and another case of spice products. At least (b)(4) bags within each case were rodent gnawed where paprika spilled out and onto other bags within the box. REPs, rodent hairs, and rodent nesting material were observed in each box and on, around, and inside (b)(4) of paprika.\n\nOn May 9, 12, 16, and 17, 2022, one rodent gnawed cardboard case having REPs and rodent rub marks contained at least (b)(4)\u002F4 oz. retail bags of (b)(4) Cumin Seeds. Inside of the box there were at least 2 rodent gnawed bags, and at least 50 REPs, rodent nesting material, and a dead and decayed rodent all nestled within the bags of cumin seeds. The box was located on a pallet at the southwest corner of the room.\n\nOn May 9, 12, 16, and 17, 2022, one cardboard case was observed to contain 10 packs of 6\u002F50g boxes of Shan Seasoning Mix Fish Biryani (mix for Spicy Fish Pilaf). At least 5 boxes had rodent gnaw marks. At least 40 REPs were on and in between boxes of the seasoning. All boxes had rodent rub marks and rodent urine stains that made the labeling of the products mostly illegible. The case was located on a pallet against the west wall of the room.\n\nOn May 9, 12, 16, and 17, 2022, at least 2 rodent gnawed holes, rodent rub marks, and at least 30 REPs were observed on 1 cardboard case containing at least (b)(4)\u002F24 oz. bags of (b)(4) brand Wheat Pelted (Whole). Within the case, there were at least 5 bags that had rodent gnaw marks where wheat pellet product had spilled out and onto other bags. REPs and rodent nesting material were in the case and inside the rodent gnawed bags. This case was located on boxes along the southwest corner of the room.\n\nOn May 9, 12, 16, and 17, 2022, one rodent gnawed cardboard case was observed to contain at least (b)(4)\u002F4 oz. retail bags of (b)(4) Granulated Garlic. Within the box there were at least 2 bags that had rodent gnawed holes along with at least 15 REPs on and in between bags. The case was located on the pallet at the southwest wall of the room.\n\nOn May 9, 12, 16, and 17, 2022, one cardboard case located on the floor (along with other cases of food products) at the south wall contained at least 5 rodent gnawed bags of (b)(4) tea sweetener and at least 9 rodent gnawed boxes labeled (b)(4) brand. REPs and rodent nesting material were inside every bag, as well as on and in between every box. Rodent rub marks and rodent urine stains on the boxes made the labeling of most boxes illegible.\n\nOn May 9, 12, 16, and 17, 2022, one cardboard case was observed with at least three apparent rodent gnaw marks containing approximately (b)(4)\u002F6 pack shrink wrapped packages of (b)(4) boxes of Shah brand Punjabi Yakhni Pilau. Within this case, there were at least five boxes that had apparent rodent gnaw marks. And at least 20 REPs and apparent rodent urine staining were observed on at least 16 boxes. The case was located along the south wall of the room.\n\nOn May 9, 12, 16-19, and 23, 2022, a large hole (approximately 2’ x 4”) surrounded by sagging sheet rock with black and brown stains was observed in the ceiling above pallets of packaged food product and paper records at the east end of the room. At least 50 REPs, rodent nesting material (including wads of pink insulation) and apparent rodent hairs were on and within 3 opened boxes of paper records below this hole.\n\nOn May 19, 2022, after all food products were removed from the storage room, hundreds of REPs, spilled spice products, fragments of rodent gnawed food packing, and rodent nesting material were on the floor of the room. One dead rodent was on the floor at the north wall near the entrance to the room. Two holes, each 3” x 3” and each containing REPs and rodent nesting material, were observed in the south and west walls. These holes were not observed previously during the inspection due to pallets of boxes of spice products stored next to each other and up against walls.\n\nSouthwest side of the warehouse\n\nOn May 9, 12, 16-19, and 23, 2022, at least 200 apparent REPs were observed on a box of incense sticks on the top layer of a pallet containing (b)(4) boxes. At least 10 REPs were found on a box of the (b)(4) layer of this pallet. The pallet was located at the north end of the warehouse and immediately adjacent to pallets of spice products, including Shan brand Fish Marsala.\n\nNorthwest side of the warehouse\n\nOn May 23, 2022, three apparent REPs were observed on 40 lb. bags of (b)(4) brand basmati sela rice on a pallet containing (b)(4) bags. One bag on this pallet had an apparent rodent gnawed hole approximately 3” x 3” that was surrounded by yellowish stains.\n\nInside (b)(4) freezer at the northwest end of warehouse\n\nOn May 17, 2022, an apparent rodent urine stain, approximately 1\u002F2” x 2”, was observed on the floor below returned food products along the southwest wall. Within the (b)(4) freezer, pallets of boxes of food products were stored up against walls and immediately adjacent to each other within the aisles of the pallet racks. There were no aisles in between the pallets and the racks, making the center and the entire north wall inaccessible for a visual inspection.\n\nSoutheast end of the warehouse\n\nOn May 9, 12, 16-19, and 23, 2022, one dead rodent was found in tin cat #23 located at the entrance to the warehouse from the administrative offices at the southeast side.\n\nInsect activity observed:\n\nOn May 12, 2022, live and dead insects in winged, crawling and larvae forms as well as moth webbing were observed on every bag of every layer of (b)(4) pallets each containing (b)(4)\u002F55 lb. bags of (b)(4) (split chickpeas). Insect bored holes were observed in at least 4 bags of each pallet. (b)(4) product below the bored holes appeared clumped with insect eggs and had crawling insects. These pallets were located on the (b)(4) of pallet (b)(4) in the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, live and dead insects in winged, crawling and larvae forms were observed on and inside several opened bags of products including cashews, cumin spice, curry spice, fennel, bay leaves, legumes, and cinnamon that were in a pile with other food products on the floor of the repack room located at the south end of the warehouse.\n\nOn May 23, 2022, an opened, unlabeled cardboard case (3’ x 3’) containing yellow legumes had live and dead insects on the legumes and on the plastic wrap that lightly covered the box. This box was located near the entrance to the repack room at the south end of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, live and dead insects in flying, crawling, and larvae forms were observed on and in between bags of expired Swarna brand whole wheat flour that were on (b)(4) pallets each containing at least (b)(4)\u002F20 lb. bags. Live and dead flying and crawling insects were observed on and in between the bags and shrink wrap of all (b)(4) pallets. Two opened bags contained at least 6 winged and crawling insects. The (b)(4) pallets were located next to pallets of boxes and bags of food product including basmati rice at the north end of the warehouse.\n\nOn May 23, 2022, at least 5 dead insects were observed around a 1” x 1” hole in a 25 lb. bag of expired (b)(4) brand desiccated coconut. The bag was on a pallet of (b)(4)\u002F25 lb. soiled and dirty bags located between roll up doors 2 and 3 at the east end of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, pallets of boxes of food products (including soup mixes and (b)(4) brand drinks) returned from a customer that were observed damaged, dirty, and showing insect activity were commingled with food products intended for sale along the east and west sides of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, dead and\u002For live cockroaches were found in 18 tin cats staged round the inside perimeter of the warehouse. These included 34 live and dead cockroaches in tin cat #4 located between roll up doors 2 and 3 along the east wall; 30 live and dead cockroaches in tin cat #10 at the north wall; 70 live and dead cockroaches in tin cat# 14 at the west wall; and 49 live and dead cockroaches in tin cat #17 at the southwest wall.\n\nOn May 16, 2022, live and dead insects in winged, crawling and larvae forms were found on and around boxes and bags of various food products (including basmati rice) located at each pallet rack within the center of the warehouse.\n\nAnimal activity observed:\n\nOn May 9, 12, 16-19, and 23, 2022, piles of cat feces were observed on the floor at the north wall, northeast corner, south wall, southeast corner, west wall, and northwest corner of the warehouse. A pile of cat feces was also observed under pallet (b)(4) beneath boxes of soft drink beverage products.\n\nOn May 17, 2022, at least 4 empty bags of dried cat food were observed in the room above the repack room. Animal paw prints were observed on dusty boxes (holding food products such as (b)(4) instant mix) located at the north, south, and southwest ends of the warehouse. Animal paw prints were observed on boxes of (b)(4) brand cookies located on a pallet near the entrance to the dry storage room.\n\nOn May 12, 2022, cat urine was identified on 2\u002F55 lb. bags of (b)(4) (split chickpeas) that were located on layers (b)(4) pallet containing (b)(4)\u002F55 lb. bags. This pallet was located on the (b)(4) of pallet (b)(4). A bag of (b)(4) product on the top layer was found saturated with cat urine.\n\nOn May 18, 2022, at approximately 11:00 AM, one live apparent bat was observed flying in circles and landing in the seam between two concrete slabs and a wooden ceiling joist along the south wall between the dry goods storage room and the west wall of the warehouse.\n\nStructural deficiencies observed:\n\nOn May 9, 12, 16-19, and 23, 2022, a gap approximately 2’ x 4” was observed at the upper right side of the closed rollup door #1 at the east end of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, a hole approximately 3” x 3” was observed at the left side and base of closed roll up door #2 at the east end of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, a gap approximately 2” x 1” was observed at the center and base of closed roll up door #3 at the east end of the warehouse.\n\nOn May 9, 12, 16-19, and 23, 2022, a pedestrian door #10, located at the northeast end of the warehouse, was ajar and held closed with a belt. There was a 1”- 3” gap that spanned the base of the door, and a 1 ½’ x 3” gap along the lower right side of the door.\n\nOn May 9, 12, 16-19, and 23, 2022, a gap approximately 1” to 3” was observed at the base of the closed pedestrian door, located at tin cat #12 at the northwest end of the warehouse.\n\nHarborage areas inside the warehouse observed:\n\nOn May 9, 12, 16-19, and 23, 2022, pallets of boxes of Shan brand food products (including pickles and spices) were stored immediately adjacent to each other and up against walls all along the north wall of the warehouse. Tin cats # 6, 8, and 9 placed by the pest control provider along the north wall were either missing or inaccessible.\n\nOn May 9, 12, 16-19, and 23, 2022, pallets of boxes of food products returned from customers that were damaged, dirty, and showing insect or rodent activity were commingled with products slated for sale to customers along the east and west sides of the warehouse.\n\nPest control records:\n\nIn addition to visual observations, our investigators conducted a review of your third-party pest control provider inspection reports which revealed the following:\n\nReport dated 11\u002F20\u002F2019 showed the technician observed \"Gaps on all exterior doors - All man doors and roll up doors have gaps at the bottom of the entrance allowing insect and rodent presence.\"\n\nReport dated 04\u002F30\u002F2020 showed the technician observed “food product all over the floor that is giving insects and rodents a food source, weeds around the structure, damaged food inside multiple opened containers and pallets of food located on the north and west side of the building, and multiple pallets stored too closely to the north wall of the facility giving rodents and insects harboring areas.\" The technician recommended that the firm \"clean up the property.\"\n\nReport dated 06\u002F05\u002F2020 showed rodent activities and cat activities inside the warehouse. Technician noted no changes to the containers (doors kept open) and improper storage throughout the perimeter wall and exterior of the building as observed on 04\u002F30\u002F2020. Technician also noted \"heavy pigeon activity and droppings\" and that he found a litter of cats inside of the warehouse that were being fed by employees. It was noted that areas were not being cleaned and sanitized as needed and that there was a need to re-evaluate the account to continue to provide their services to this site.\n\nReport from 08\u002F07\u002F2020 showed rodent activity and cat feces throughout the facility. Technician observed and noted a cat sleeping on “expired pallets” and heavy cat droppings on the west side of the building between the cooler and the west side interior walls. Technician noted that there were still pallets and shipping containers with damaged and outdated product being stored outside that needed to be removed.\n\nReports in 2021 consistently showed rodent activities, cat droppings in the warehouse, pallets with food leading to pest harborage\u002Fattractant, in addition to activities of Oriental and Turkistan roaches, ants, and bats. On 06\u002F14\u002F2021, the technician noted that he \"found a pallet of cornmeal near trap 7 that was infested with stored product pest\" and that \"this pallet should be removed immediately.\" Also, on 08\u002F26\u002F2021, the technician noticed \"Indian meal moth activity that is most likely coming from old, expired product that is sitting in the warehouse.\" On 10\u002F25\u002F2021 and 11\u002F23\u002F2021, the technician noted some of the traps were inaccessible for inspection.\n\nReports dated 04\u002F22\u002F2022, 03\u002F22\u002F2022, 02\u002F22\u002F2022, and 01\u002F24\u002F2022 showed the technician repeatedly stated: “Gaps on all exterior doors[.] [A]ll pedestrian doorways and roll up doors have gaps at the bottom of the entrance allowing insects and rodent presence. Food product throughout the warehouse[.] [T]here is food product all over the floor that is giving insects and rodents a food source. Damaged food on the north and west side of the building[.] [T]here are multiple shipping containers that are opened with damaged food product[,] and there are multiple pallets that are damaged with food product on it. On the north side of the facility there are multiple pallets that are too close to the structure giving rodents and insects harboring areas.”\n\nSamples\n\nFDA collected several samples during the inspection (samples 1184925, 1176915, 1182925, 1183037 and 1183038). These samples were submitted to FDA labs for analysis. Results demonstrate that submitted product [including (b)(4) (split chickpeas) and (b)(4) brand Paprika] were contaminated with rodent\u002Fmouse hairs, cat hair and urine, urine stains (on packaging), gnaw marks, REPs as well as various species of larval, pupal, and adult insects. Further, sample 1184925 had evidence of insect penetration and damage to packaging and product as well as urine stains and yeast. The filth samples further demonstrated the presence of rodents and insect activity throughout the facility through the presence of rodent hairs, teeth marks, in pellet morphology and nesting materials as well as confirmation of various species of insects at larval, pupae and adult stages.\n\nYour June 7, 2022, written response indicated that you contracted with a new third-party pest control provider and increased service frequency (b)(4) a month. In addition, you described a treatment plan to gain control of your facility and remove all pest activity from the interior and exterior. Further, you provided service reports dated 05\u002F26, 05\u002F27, 05\u002F31, and 06\u002F03\u002F2022; however, these reports do not show the frequency for routine service. Also, you did not provide confirmation of other actions promised by your response, such as (b)(4) application over a (b)(4) period, a (b)(4) rodent trapping program, and establishment of a bat exclusion program.\n\nIn addition, your response indicated that all gaps and holes in doors have been repaired to eliminate pest route of entry. Further, you stated all areas of the facility, including warehouse, dry storage, walk-in freezer and packing room have been cleaned to remove rodent, animal, and insect filth. You also indicated that all affected product (damaged, expired, or containing urine stains or REPs) has been removed and discarded and that pallets have been moved away from walls for accessibility. However, you did not provide documentation to demonstrate repairs were made and the effectiveness of cleaning and pest removal, with the exception of the dry storage room. Further, you did not indicate how you plan to continue to maintain the facility and equipment in a sanitary condition.\n\n2. You failed to properly store equipment, remove litter and waste, and cut weeds and grass that may constitute an attractant, breeding place, or harborage for pests within the immediate vicinity of the plant, as required by 117.20(a)(1). Specifically,\n\nOn May 9, 12, 16-19, and 23, 2022, piles of damaged pallets, pipes, garbage and boxes of food products (including (b)(4) brand mango juice drinks and (b)(4) brand mango fruit nectar drinks) were along the north side of the building, by the dumpsters in the parking lot at the east end of the warehouse\n\nOn May 12, 17-19, and 23, 2022, at least (b)(4) pallets of boxes of food product (including (b)(4) brand fun snacks rice bites and Shan brand Shoop Instant noodles) were located at the northwest end. Bird feces was on the concrete pavement around the pallets of products.\n\nOn May 12, 17-19, and 23, 2022, several piles of broken pallets, unused equipment, and garbage were all along the fence line outside the west end of the firm.\n\nOn May 12, 17-19, and 23, 2022, three opened shipping containers, located outside at the west and northwest ends of the warehouse, each contained pallets of dirty and damaged boxes and bags of food products. Some bags and boxes were torn open where food product spilled out on to the floor and outside of the containers. All products within all three containers were haphazardly arranged, immediately adjacent to each other, and up against the sides of the containers. There were no aisles between products that would allow for a visual inspection within any of the containers.\n\nOn May 9, 12, 16-19, and 23, 2022, overgrown weeds spanned along the fence lines at the north and northwest sides of the warehouse.\n\nOn May 17, 2022, one live adult cat and 5 kittens were observed on top of a pallet of boxes of Falak brand basmati rice stored in an opened shipping container located outside of the warehouse at the west end.\n\nIn addition, on May 12, 2022, the following food products slated for destruction were located outside on your grounds:\n\n(b)(4) pallets containing boxes of prepackaged drinks were observed stored outside at the northeast wall.\n\n(b)(4) pallets of boxes of food products (including (b)(4) Brand fun snacks rice bites and Shan brand Shoop instant noodles) were observed outside at the northwest wall.\n\n(b)(4) opened shipping containers, (b)(4) at the northwest wall and (b)(4) at the west wall, all containing stacks of bags of dirty, dusty food products including legumes and pallets of boxes of food products including basmati rice that were observed immediately next to each other and up against the walls. There were no aisles in between products that would allow for a visual inspection of the containers. You did not start destroying products until May 23, 2022, after CDPH placed your firm under a blanket embargo on May 17, 2022.\n\nYour Inventory Controller could not provide an estimate as to how long the food slated for destruction had been kept outside. This employee stated that dumpsters were ordered but could not give a time frame as to when they would arrive.\n\nFurther, on May 23, 2022, hundreds of apparent REPs were found around all 6 downspouts of the gutter drainage systems outside and along the south wall of the firm. At least 100 apparent REPs were found around the downspout nearest to the visitor’s entrance of the firm. At least 300 apparent REPs were found around the 3rd downspout located at the center of the south wall. Apparent rodents were heard moving about the inside of the piping system that led this downspout.\n\nYour June 7 response stated that all food product and food debris have been discarded from the yard area damaged pallets and materials have been removed, and the grounds have been cleaned to remove pests, litter, trash, spoiled food, and feces. You also indicated that four storage containers have been emptied, cleaned and the product discarded. However, you did not provide documentation to demonstrate that these activities were performed, with the exception of one photograph of the grounds along an unidentified exterior wall. Further, you did not indicate how you plan to continue to maintain your yard in a sanitary condition.\n\nYour written response also described processes established for the management of product slated for destruction. We are not able to fully evaluate the adequacy of this corrective action as you did not provide supporting documentation of its implementation.\n\n3. You did not maintain your plant in a clean and sanitary condition and keep your plant in repair adequate to prevent food from becoming adulterated, as required by 21 CFR 117.35(a). Insanitary conditions around your facility demonstrated that sanitation and housekeeping operations were inadequate because your facility provided food sources and pest harborage areas for rodents and other pests which led to widespread product contamination. In addition, inadequate maintenance to parts of the facility allowed for potential pest entry and harborage areas within the facility. Specifically, during the inspection, on May 9, 2022, your firm identified 28 products that may be repacked in a dedicated room at your firm. Among these items are cashews, almonds, cumin powder, cloves, cinnamon, cardamom, and coriander that may be ready-to eat (RTE) and (b)(4) packaged by employees within an open environment. The following was observed in your repack room during the inspection:\n\nOn May 9, 12, 16-19, and 23, 2022, buildup of dirt and dust debris on all (b)(4) hoppers\u002Fproduct filling equipment, scales, and shelves. Food debris, including garbanzo beans, was observed inside, and dusty dirty kidney beans and legumes were observed around the framing of one of the hoppers.\n\nOn May 9, 12, 16-19, and 23, 2022, food products, including bay leaves, fennel seeds, and legumes, were spilled on the floor and on pallets about the room.\n\nOn May 9, 12, and 16-19, 2022, a pile of at least 30\u002F4 oz. retail packages red legumes was on the floor near the entrance to the repack room.\n\nOn May 9, 12, 16-19, and 23, 2022, empty drink containers and food packages were found on shelves and in between bags and boxes of food products.\n\nOn May 9, 12, 16-19, and 23, 2022, opened bags of food products including spices and cashews were observed in a large pile on the floor and up against the south wall. Live and dead insects were observed on and inside of the opened bags of product.\n\nOn May 9, 12, 16-19, and 23, 2022, a (b)(4) sink and an adjacent white sink were located at the east end of the room. Both had a build-up of dust and dirt, and a spider web spanned across one basin of the (b)(4) sink. There was no soap, towels, or other means to dry hands at either sink. Your Inventory Controller stated the sinks are not used.\n\nYour June 7 response stated the packing room and equipment within have been cleaned and sanitized to remove dust and food debris. You also indicated that all infested product has been removed and discarded. Further, packaging materials have been cleaned. FDA will evaluate the adequacy cleaning and sanitation practices during our next inspection of your facility. Your written response described re-packing and record keeping processes which have been created; however, we are not able to fully evaluate the adequacy of this corrective action as you did not provide supporting documentation of its implementation.\n\n4. You did not provide employees with adequate, readily accessible, and clean toilet facilities to prevent a potential source of contamination of food, food-contact surfaces, or food packaging materials, as required by 21 CFR 117.35(d). Specifically:\n\nOn May 9, 12, 16, 17 and 23, 2022, the faucet, located inside the restroom, of the designated handwashing sink was covered with plastic wrap obstructing the use of the sink. There were no soap, towels, or other means to dry hands at this sink.\n\nOn May 9, 12, 16, 17 and 23, 2022, within the janitorial area, between the 2 toilets in the room, there was a sink, located in the restroom, that did not have towels or other means to dry hands, and there was no soap but rather a bottle of shampoo next to the faucet.\n\nYour June 7 response stated that the employee and office bathrooms have been cleaned and fully stocked with hand soap, paper towels, toilet paper and seat-covers. It also stated that all sinks have been repaired, have hot and cold running water, and are stocked with hand soap and paper towels. Although you provided photographs which show the re-packaging equipment appears to be in sanitary condition, you did not provide photographs or other evidence to demonstrate the condition of the room or sinks. Also, you provided photographs to show a restroom and handwash station were cleaned and stocked appropriately; however, the locations are unknown. Further, you did not indicate how you plan to continue to maintain the facility (including bathrooms) in a sanitary condition. FDA will evaluate the adequacy cleaning and sanitation practices during our next inspection of your facility.\n\nMisbranding\n\n1. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(w) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(w)] in that the finished product label fails to declare the major food allergen, milk. According to the label, this product is made from “Pure Grade AA Clarified Butter”, which is made from milk. We point out that in your response to the 483 (corrective action plan), there was no mention of correcting the labels.\n\n2. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(a)] because there is a large discrepancy between serving size and servings per container information provided in the Nutrition Facts Label, when compared to the declared net quantity of contents. The net quantity of contents is double what would be calculated for the net quantity based on the information in the Nutrition Facts Label. If the declared serving size of 13g is multiplied by the declared 35 servings per container, the result is 455g, which is about one pound. However, the net quantity of contents for the product is declared as 2lb (32 FL OZ).”\n\n3. Your 100% Pure Desi Ghee product is misbranded within the meaning of section 403(q) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(q)] because the serving size is not based on the appropriate RACC in accordance with 21 CFR 101.12(b)] and (21 CFR 101.9(b); therefore, all of the values in the nutrition label are incorrect. The label indicates a serving of “1\u002F2 cup” (13 g). The RACC for this product is under the category “Butter, margarine, oil, shortening” and has a reference amount of 1 tbsp and a label statement of “1 tbsp (g) or 1 tbsp(15 mL).” Furthermore, we question whether ½ cup of this product would weigh 13 grams.\n\n4. Your 100% Pure Desi ghee product is misbranded within the meaning of section 403(f) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(f)] because “desi” is a Hindi term; therefore, all required (mandatory) labeling must also be in Hindi, in accordance with section 21 CFR 101.15(c)(2).\n\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nAdditionally, we reviewed your Shah Brand ghee product label and offer the following comments:\n\nGhee is obtained from milk, cream or butter by removing the non-fat milk solids and water, and it typically contains about 99.6% or more milk fat (Codex Standard CXS 280-1973). Ghee is not considered a highly refined oil and is not exempt from major food allergen labeling requirements. Since ghee is prepared from milk, a major food allergen, the label must declare milk as the name of the food source from which the major food allergen is derived.\n\nThe amount of non-fat milk solids, including milk proteins, present in ghee can vary depending on manufacturing process. The protein content of the ghee product must be determined for better evaluation of the risk posed by milk proteins remaining in ghee. The protein content in the Shah Brand ghee product is not known. The Nutrition Facts panel of its label indicates a serving size of ½ cup (13 g) and 7g protein, which do not appear to be accurate. A search for nutrient composition of ghee at USDA database indicate 0.28% protein in ghee1. This is equivalent to 0.039 g (39 mg) milk protein in a portion of 14 g (1 tablespoon) ghee. The current science on allergen risk assessment is based on population minimal eliciting dose (ED) distributions, which can be used to determine ED01 and ED05 doses at which 1% and 5% of the allergic population, respectively, can be expected to have allergic reaction1. Remington et al (2020)22estimated ED01 and ED05 for milk protein to be 0.2 mg and 2.4 mg, respectively, which is considerably lower than the milk protein that could be expected in 1 tablespoon of ghee. It can be anticipated that a serving size of 1 tablespoon ghee with 39 mg milk protein can possibly cause allergic reaction in over 25% of milk allergic population based on the ED25 of 32.7 mg for milk protein reported by Houben et al (2020)33. We consider the milk proteins remaining in ghee can pose a significant concern of allergic reaction in milk allergic population.\n\nWe also note the following:\n\nThere is inconsistency within your label’s net quantity of comments statement in that it lists both “NET WT.” and “FL OZ.” 21 CFR 101.7(a).\n\nThe information panel is not immediately to the right of the principal display panel, as required by section 21 CFR 101.2.\n\nThe street address for your firm is not provided. In accordance with section 21 CFR 101.5(d), the street address is required unless it is shown in a current city directory or telephone directory.\n\nThe trans-fat declaration is not expressed in the correct increment as required by section 21 CFR 101.9(c)(2)(ii), and the vitamins and minerals are not declared in accordance with the new Nutrition Facts label (NFL). As you may already know, FDA finalized new requirements for nutrition labeling on May 27, 2016. The new Nutrition Facts label includes updates to the required nutrient declarations and formatting requirements. For more information on the new requirements, please see http:\u002F\u002Fwww.fda.gov\u002FFood\u002FGuidanceRegulation\u002FGuidanceDocumentsRegulatoryInformation\u002FLabelingNutrition\u002Fucm385663.htm.\n\nPlease notify this office in writing within fifteen (15) working days of the receipt of this letter, as to the specific steps that you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number CMS# 635805 when replying.\n\nIf you prefer to send your response electronically, please email it to ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and the Unique Identification number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5\n\n________________________\n\n1 USDA website link FoodData Central (usda.gov).\n\n2 Remington et al, 2020, Updated population minimal eliciting dose distributions for use in risk assessment of 14 priority food allergens. Food and Chemical Toxicology, 139: 111259.\n\n3 Houben et al, 2020, Full range of population eliciting dose values for 14 priority allergenic foods and recommendations for use in risk characterization. Food and Chemical Toxicology, 146: 111831.","Gold Coast Distributors Inc. dba Shah Distributors","gold-coast-distributors-inc-dba-shah-distributors-635805-11022022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgold-coast-distributors-inc-dba-shah-distributors-635805-11022022","2026-10-26T08:08:47.660606+00:00","2023-01-24","635805","Mr. Sourabh Roy","2026-08-20T01:18:17.949+00:00","2022-11-02",{"id":176,"raw":177,"subject":12,"body_html":181,"body_text":182,"firm_name":183,"letter_id":184,"created_at":83,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":189,"body_fetched_at":190,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":187,"medical_device_id":19,"response_letter_date":19},1775,[178,179,180,11,12,13,13,13],"\u003Ctime datetime=\"2023-11-02T19:00:00Z\">11\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-02T04:00:00Z\">11\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwolfe-trading-company-llc-dba-east-coast-vapors-665863-11022023\">Wolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Wolfe\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Wolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>346 Ritchie Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Severna Park\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21146\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wolfejammer@gmail.com\"> wolfejammer@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 2, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wolfe:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Wolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Katy Perry.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300929, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJames Wolfe\n\nRecipient Title\n\nOwner\n\nWolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors\n\n346 Ritchie Highway\n\nSeverna Park, MD 21146\n\nUnited States\n\nwolfejammer@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 2, 2023\n\nWARNING LETTER\n\nDear Mr. Wolfe:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Wolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Katy Perry.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300929, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Wolfe Trading Company LLC d\u002Fb\u002Fa East Coast Vapors","wolfe-trading-company-llc-dba-east-coast-vapors-665863-11022023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwolfe-trading-company-llc-dba-east-coast-vapors-665863-11022023","2026-10-26T08:10:33.082269+00:00","2023-11-02","665863","James Wolfe","2026-08-20T00:34:08.966+00:00",{"id":192,"raw":193,"subject":12,"body_html":197,"body_text":198,"firm_name":199,"letter_id":200,"created_at":18,"fei_number":19,"letter_url":201,"updated_at":202,"action_type":22,"case_status":23,"posted_date":203,"marcs_cms_no":204,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":205,"body_fetched_at":206,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":203,"medical_device_id":19,"response_letter_date":19},2618,[194,195,196,11,12,13,13,13],"\u003Ctime datetime=\"2022-06-23T19:00:00Z\">06\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-23T04:00:00Z\">06\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feast-coast-liquids-dba-planet-vapor-634844-06232022\">East Coast Liquids d\u002Fb\u002Fa Planet Vapor\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Moore\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>East Coast Liquids d\u002Fb\u002Fa Planet Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>912 South Lake Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lexington\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29072\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:kevin@mooredistro.com\"> kevin@mooredistro.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 23, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Moore:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that East Coast Liquids d\u002Fb\u002Fa Planet Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Space Cowboy 3MG 30ML e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 3,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003705 on September 8, 2020. However, FDA issued a negative action for STN PM0003705 in the form of a Refuse To Accept determination on June 29, 2021, which covers 978 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003705 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200579, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nEast Coast Liquids\u003Cbr>\n1328 Old Dairy Drive\u003Cbr>\nColumbia, SC 29201\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nKevin Moore\n\nRecipient Title\n\nPresident\n\nEast Coast Liquids d\u002Fb\u002Fa Planet Vapor\n\n912 South Lake Drive\n\nLexington, SC 29072\n\nUnited States\n\nkevin@mooredistro.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 23, 2022\n\nWARNING LETTER\n\nDear Mr. Moore:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that East Coast Liquids d\u002Fb\u002Fa Planet Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Space Cowboy 3MG 30ML e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 3,600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003705 on September 8, 2020. However, FDA issued a negative action for STN PM0003705 in the form of a Refuse To Accept determination on June 29, 2021, which covers 978 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003705 that resulted in a Refuse To Accept determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200579, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc:\n\nEast Coast Liquids\n\n1328 Old Dairy Drive\n\nColumbia, SC 29201","East Coast Liquids d\u002Fb\u002Fa Planet Vapor","east-coast-liquids-dba-planet-vapor-634844-06232022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feast-coast-liquids-dba-planet-vapor-634844-06232022","2026-10-26T08:08:30.27658+00:00","2022-06-23","634844","Kevin Moore","2026-08-20T01:49:39.742+00:00",{"id":208,"raw":209,"subject":12,"body_html":213,"body_text":214,"firm_name":215,"letter_id":216,"created_at":217,"fei_number":19,"letter_url":218,"updated_at":219,"action_type":22,"case_status":23,"posted_date":220,"marcs_cms_no":221,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":222,"body_fetched_at":223,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":220,"medical_device_id":19,"response_letter_date":19},3589,[210,211,212,11,12,13,13,13],"\u003Ctime datetime=\"2021-01-15T14:20:00Z\">01\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-15T05:00:00Z\">01\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoastal-e-liquid-laboratorygc-vapors-llc-612795-01152021\">Coastal E-Liquid Laboratory\u002FGC Vapors LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark LaFontaine\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Coastal E-Liquid Laboratory\u002FGC Vapors LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3073 Big Ridge Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>D’Iberville\u003C\u002Fspan>, \u003Cspan>MS\u003C\u002Fspan> \u003Cspan>39540\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:gcvaporshr@gmail.com\"> gcvaporshr@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@coastaleliquidlab.com\"> info@coastaleliquidlab.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@gcvapors.com\"> info@gcvapors.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Dear Mark LaFontaine:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fgcvapors.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. §&nbsp;321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption.&nbsp; Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. §&nbsp;387a(b)) and 21 C.F.R. § 1100.1. &nbsp;Therefore, e-liquids are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act.&nbsp; These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco.&nbsp; \u003Ci>See\u003C\u002Fi> Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Cu>\u003Cspan>\u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fu>\u003C\u002Fspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)).&nbsp; Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Our review of the website https:\u002F\u002Fgcvapors.com revealed that you manufacture and offer for sale or distribution\u003Cb> \u003C\u002Fb>to customers in the United States e-liquid products without a marketing authorization order including: Amaretto and Lavender.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007.&nbsp; These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act.&nbsp; In addition, these products are\u003Cb> \u003C\u002Fb>misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. \u003C\u002Fspan>\u003Cb>&nbsp;\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>Conclusion and Requested Actions\u003Cu> \u003C\u002Fu>\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Your firm is a registered manufacturer with over 23,200 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations.\u003C\u002Fspan>&nbsp; \u003Cspan>Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction.&nbsp; However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act.&nbsp; Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fhome\">http:\u002F\u002Fwww.fda.gov\u003C\u002Fa>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please note your reference number, RW2101469, in your response and direct your response via email at \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa> and to the following address: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301)&nbsp;796-9235 \u003Cspan>or via email at\u003C\u002Fspan> \u003Ca href=\"mailto:CTPCompliance@fda.hhs.gov\">CTPCompliance@fda.hhs.gov\u003C\u002Fa>.&nbsp; &nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Ann Simoneau, J.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance and Enforcement \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Tobacco Products\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>VIA UPS and Electronic Mail\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cc:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GC Vapors, LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>Attn: Mark LaFontaine\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>4020 Popps Ferry Rd Suite A\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>D’Iberville, MS 39540\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GC Vapors Lemoyne Blvd\u002FGC Management, Inc.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>16201 Lemoyne Blvd\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Biloxi, MS 39532\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>GoDaddy.com, LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>abuse@godaddy.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Google LLC\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Google-cloud-compliance@google.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMark LaFontaine\n\nCoastal E-Liquid Laboratory\u002FGC Vapors LLC\n\n3073 Big Ridge Rd\n\nD’Iberville, MS 39540\n\nUnited States\n\ngcvaporshr@gmail.com\n\ninfo@coastaleliquidlab.com\n\ninfo@gcvapors.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mark LaFontaine:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fgcvapors.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquids are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fgcvapors.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: Amaretto and Lavender.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 23,200 products listed with FDA. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101469, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nGC Vapors, LLC\n\nAttn: Mark LaFontaine\n\n4020 Popps Ferry Rd Suite A\n\nD’Iberville, MS 39540\n\nGC Vapors Lemoyne Blvd\u002FGC Management, Inc.\n\n16201 Lemoyne Blvd\n\nBiloxi, MS 39532\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nGoogle LLC\n\nGoogle-cloud-compliance@google.com","Coastal E-Liquid Laboratory\u002FGC Vapors LLC","coastal-e-liquid-laboratorygc-vapors-llc-612795-01152021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoastal-e-liquid-laboratorygc-vapors-llc-612795-01152021","2026-10-26T08:08:16.558303+00:00","2021-01-15","612795","Mark LaFontaine","2026-08-20T03:27:25.719+00:00",{"id":225,"raw":226,"subject":232,"body_html":233,"body_text":234,"firm_name":235,"letter_id":236,"created_at":237,"fei_number":19,"letter_url":238,"updated_at":239,"action_type":22,"case_status":23,"posted_date":240,"marcs_cms_no":241,"product_type":242,"closeout_date":19,"issuing_office":230,"recipient_name":243,"body_fetched_at":244,"delivery_method":245,"recipient_title":19,"reference_number":246,"action_taken_date":247,"medical_device_id":19,"response_letter_date":19},336,[227,228,229,230,231,13,13,13],"\u003Ctime datetime=\"2026-02-10T05:00:00Z\">02\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-29T05:00:00Z\">01\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-coast-multispecialty-medical-group-inc-722521-01292026\">Central Coast Multispecialty Medical Group, Inc. \u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-722521\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward J. Ramirez, MD, FACOG\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Medical Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Central Coast Multispecialty Medical Group, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9833 Blue Larkspur Ln\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Monterey\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>93940\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ejrmd@montereybayivf.com\"> ejrmd@montereybayivf.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CBER 26-722521\u003C\u002Fp>\u003Cp>January 29, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Ramirez:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Central Coast Multispecialty Medical Group, Inc., located at 9833 Blue Larkspur Lane, Monterey, CA, conducted between May 13, 2025, and May 16, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\u003Cp>The observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1) &nbsp; Failure to screen a donor of reproductive cells or tissue by reviewing the donor’srelevant medical records for risk factors for, and clinical evidence of, relevantcommunicable disease agents and diseases [21 CFR 1271.75(a)(1)]. Your firm’sDonor Eligibility Questionnaire and Donor Medical History Interview Form areused as relevant medical records to determine donor eligibility. However, yourforms do not include screening for all conditions and\u002For behaviors that increase adonor’s relevant communicable disease risk. For example, the Donor EligibilityQuestionnaire form submitted with your FDA 483 response is missing questions,timeframes, and\u002For deferral periods to assess a donor’s relevant communicabledisease risk for the following:\u003C\u002Fp>\u003Cp>a. Question 5 fails to screen for persons who have had sex in the preceding 12 months with any person who has had sex with a man who has had sex with another man in the preceding 5 years, persons with \u003Cstrong>hepatitis B infection\u003C\u002Fstrong> (both active and inactive) or \u003Cstrong>clinically active (symptomatic)\u003C\u002Fstrong> \u003Cstrong>hepatitis C infection\u003C\u002Fstrong>, persons who have injected drugs for a non-medical reason in the preceding 5 years, including intravenous, intramuscular, or subcutaneous injections, and persons who have engaged in sex in exchange for money or drugs in the preceding 5 years.\u003C\u002Fp>\u003Cp>b. Question 8 states, “Have you within the past 12 months of donation undergone tattoing [sic], ear piercing, or body piercing in which shared instruments are known to have been used.” The question needs to also ask whether sterile procedures were not used.\u003C\u002Fp>\u003Cp>c. Question 11 states, “Have you had a recent smallpox vaccination (vaccinia virus) in the last 21 days?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to ask about smallpox vaccination (vaccinia virus) in the preceding \u003Cstrong>8 weeks\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>d. Question 13 states, “Have you had a medical diagnosis of West Nile Virus Infection within the last 120 days (including diagnosis based on symptoms and laboratory results, or confirmed WNV viremia)?” You do not include “suspicion” in your form or equivalent terminology to adequately screen for this illness.\u003C\u002Fp>\u003Cp>e. Your form fails to adequately screen for persons who have spent 3 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> in the UK between 1980 and 1996. Without “cumulatively” or similar language the question is under-inclusive.\u003C\u002Fp>\u003Cp>f. Your form fails to adequately screen for persons who are current or former U.S. military members, civilian military employees, or dependents of a military member or civilian employee who resided at U.S. military bases in Northern Europe (Germany, Belgium, and the Netherlands) for 6 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> from 1980 through 1990, or elsewhere in Europe (Greece, Turkey, Spain, Portugal, and Italy) for 6 months or more \u003Cstrong>cumulatively\u003C\u002Fstrong> from 1980 through 1996. Without “cumulatively” or similar language the question is under-inclusive.\u003C\u002Fp>\u003Cp>g. Your form fails to screen for persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from 1980 through 1996).\u003C\u002Fp>\u003Cp>h. Your question 29 states, “Have you had close contact within 12 months preceding donation with another person having clinically active viral hepatitis?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to also ask about persons who have lived with (resided in the same dwelling) another person who has \u003Cstrong>hepatitis B\u003C\u002Fstrong> or \u003Cstrong>clinically active (symptomatic) hepatitis C\u003C\u002Fstrong> infection in the preceding 12 months.&nbsp;\u003C\u002Fp>\u003Cp>i. Your form fails to screen for persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\u003C\u002Fp>\u003Cp>2) Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1), (b), or (c) [21 CFR 1271.75(d)]. For example, directed semen donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> answered \"yes\" to question 1 on your \u003Cem>Donor Medical History Interview Form\u003C\u002Fem>, “(Men only) Have you had sex with another man in the preceding five years?” Donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined “eligible” on May 9, 2025.\u003C\u002Fp>\u003Cp>3) Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. The eligibility of donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. For example, directed semen donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was determined “eligible” on May 9, 2025, but the results of donor testing for \u003Cem>Chlamydia trachomatis\u003C\u002Fem>, \u003Cem>Neisseria gonorrhea\u003C\u002Fem>, and HIV\u002FHCV\u002FHBV NAT were not received until May 10, 2025.\u003C\u002Fp>\u003Cp>The violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\u003C\u002Fp>\u003Cp>Additional information regarding the regulation of HCT\u002FPs is available at:\u003C\u002Fp>\u003Cul>\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\u003C\u002Fli>\u003Cli>https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fbiologics-guidances\u002Ftissue-guidances\u003C\u002Fli>\u003Cli>FDA Workshop for the Reproductive Tissue Industry - Sept 29 and Oct 1, 2020 - 09\u002F29\u002F2020 - 10\u002F01\u002F2020 | FDA\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We acknowledge receipt of your letter, dated May 28, 2025, providing a response to the FDA’s inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\u003C\u002Fp>\u003Cp>1) We acknowledge the revisions made to your Donor Eligibility Questionnaire submitted with your response. However, our review of this questionnaire identified additional deficiencies as outlined in this letter.\u003C\u002Fp>\u003Cp>2) Regarding Observations 1 and 2, your response does not address the required labeling in accordance with 21 CFR 1271.65(b)(2). All donors, except as provided under 21 CFR 1271.90, are required to be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (21 CFR 1271.75(a)) and tested for relevant communicable diseases (21 CFR 1271.80). Please note, an HCT\u002FP from a donor who has been determined to be ineligible, based on the results of required testing and\u002For screening, is not prohibited by Subpart C from use for implantation, transplantation, infusion, or transfer if the HCT\u002FP consists of reproductive cells or tissue from a directed reproductive donor as defined in 21 CFR 1271.3(l).\u003C\u002Fp>\u003Cp>3) Regarding Observation 3, you stated “The policies and procedures that are in place in regards to our treatment of Donor patients is verbally transmitted through training and continuous guidance, and we do not rely on the Donor policy book for reference or use. It is merely there to be compliant.” Please be advised, you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of 21 CFR Part 1271, Subpart C. Establish and maintain means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis.\u003C\u002Fp>\u003Cp>Please note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases and\u002For who were not appropriately screened for relevant communicable disease risk factors which includes using previous versions of donor history questionnaires that did not screen for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\u003C\u002Fp>\u003Cp>Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\u003C\u002Fp>\u003Cp>If you still have embryos in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine [21 CFR 1271.90(b)] provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\u003C\u002Fp>\u003Cp>You should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\u003C\u002Fp>\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>If you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-722521\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nEdward J. Ramirez, MD, FACOG\n\nRecipient Title\n\nExecutive Medical Director\n\nCentral Coast Multispecialty Medical Group, Inc.\n\n9833 Blue Larkspur Ln\n\nMonterey, CA 93940\n\nUnited States\n\nejrmd@montereybayivf.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nCBER 26-722521\nJanuary 29, 2026\nDear Dr. Ramirez:\nDuring an inspection of your firm, Central Coast Multispecialty Medical Group, Inc., located at 9833 Blue Larkspur Lane, Monterey, CA, conducted between May 13, 2025, and May 16, 2025, the United States Food and Drug Administration (FDA) documented significant violations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (21 CFR) Part 1271 [21 CFR 1271] and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\nThe observations documented on the Form FDA-483, List of Inspectional Observations (FDA 483), were presented to and discussed with you at the conclusion of the inspection, and following FDA’s review, your violations include, but are not limited to, the following:\n1) Failure to screen a donor of reproductive cells or tissue by reviewing the donor’srelevant medical records for risk factors for, and clinical evidence of, relevantcommunicable disease agents and diseases [21 CFR 1271.75(a)(1)]. Your firm’sDonor Eligibility Questionnaire and Donor Medical History Interview Form areused as relevant medical records to determine donor eligibility. However, yourforms do not include screening for all conditions and\u002For behaviors that increase adonor’s relevant communicable disease risk. For example, the Donor EligibilityQuestionnaire form submitted with your FDA 483 response is missing questions,timeframes, and\u002For deferral periods to assess a donor’s relevant communicabledisease risk for the following:\na. Question 5 fails to screen for persons who have had sex in the preceding 12 months with any person who has had sex with a man who has had sex with another man in the preceding 5 years, persons with hepatitis B infection (both active and inactive) or clinically active (symptomatic) hepatitis C infection, persons who have injected drugs for a non-medical reason in the preceding 5 years, including intravenous, intramuscular, or subcutaneous injections, and persons who have engaged in sex in exchange for money or drugs in the preceding 5 years.\nb. Question 8 states, “Have you within the past 12 months of donation undergone tattoing [sic], ear piercing, or body piercing in which shared instruments are known to have been used.” The question needs to also ask whether sterile procedures were not used.\nc. Question 11 states, “Have you had a recent smallpox vaccination (vaccinia virus) in the last 21 days?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to ask about smallpox vaccination (vaccinia virus) in the preceding 8 weeks.\nd. Question 13 states, “Have you had a medical diagnosis of West Nile Virus Infection within the last 120 days (including diagnosis based on symptoms and laboratory results, or confirmed WNV viremia)?” You do not include “suspicion” in your form or equivalent terminology to adequately screen for this illness.\ne. Your form fails to adequately screen for persons who have spent 3 months or more cumulatively in the UK between 1980 and 1996. Without “cumulatively” or similar language the question is under-inclusive.\nf. Your form fails to adequately screen for persons who are current or former U.S. military members, civilian military employees, or dependents of a military member or civilian employee who resided at U.S. military bases in Northern Europe (Germany, Belgium, and the Netherlands) for 6 months or more cumulatively from 1980 through 1990, or elsewhere in Europe (Greece, Turkey, Spain, Portugal, and Italy) for 6 months or more cumulatively from 1980 through 1996. Without “cumulatively” or similar language the question is under-inclusive.\ng. Your form fails to screen for persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from 1980 through 1996).\nh. Your question 29 states, “Have you had close contact within 12 months preceding donation with another person having clinically active viral hepatitis?” To adequately and appropriately reduce the risk of transmission of this disease, the question needs to also ask about persons who have lived with (resided in the same dwelling) another person who has hepatitis B or clinically active (symptomatic) hepatitis C infection in the preceding 12 months.\ni. Your form fails to screen for persons who have tested positive or reactive for WNV infection using an FDA-licensed or investigational WNV NAT donor screening test in the preceding 120 days.\n2) Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1), (b), or (c) [21 CFR 1271.75(d)]. For example, directed semen donor (b)(6) answered \"yes\" to question 1 on your Donor Medical History Interview Form, “(Men only) Have you had sex with another man in the preceding five years?” Donor (b)(6) was determined “eligible” on May 9, 2025.\n3) Failure to determine whether a donor is eligible based upon the results of donor screening in accordance with 21 CFR 1271.75 and donor testing in accordance with 21 CFR 1271.80 and 21 CFR 1271.85 [21 CFR 1271.50(a)]. The eligibility of donor (b)(6) was determined and documented prior to the receipt of the results of donor testing for relevant communicable disease agents. For example, directed semen donor (b)(6) was determined “eligible” on May 9, 2025, but the results of donor testing for Chlamydia trachomatis, Neisseria gonorrhea, and HIV\u002FHCV\u002FHBV NAT were not received until May 10, 2025.\nThe violations identified above are not intended to be an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment complies with all applicable federal regulations. You are responsible for reviewing your firm’s operations, including firms within the same organization, as a whole to ensure that you are in compliance with the law.\nAdditional information regarding the regulation of HCT\u002FPs is available at:\nhttps:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\nhttps:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fbiologics-guidances\u002Ftissue-guidances\nFDA Workshop for the Reproductive Tissue Industry - Sept 29 and Oct 1, 2020 - 09\u002F29\u002F2020 - 10\u002F01\u002F2020 | FDA\nWe acknowledge receipt of your letter, dated May 28, 2025, providing a response to the FDA’s inspectional observations. We have reviewed your response, and we have determined that the response is inadequate to address our concerns. We have the following comments regarding your FDA 483 response:\n1) We acknowledge the revisions made to your Donor Eligibility Questionnaire submitted with your response. However, our review of this questionnaire identified additional deficiencies as outlined in this letter.\n2) Regarding Observations 1 and 2, your response does not address the required labeling in accordance with 21 CFR 1271.65(b)(2). All donors, except as provided under 21 CFR 1271.90, are required to be screened by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases (21 CFR 1271.75(a)) and tested for relevant communicable diseases (21 CFR 1271.80). Please note, an HCT\u002FP from a donor who has been determined to be ineligible, based on the results of required testing and\u002For screening, is not prohibited by Subpart C from use for implantation, transplantation, infusion, or transfer if the HCT\u002FP consists of reproductive cells or tissue from a directed reproductive donor as defined in 21 CFR 1271.3(l).\n3) Regarding Observation 3, you stated “The policies and procedures that are in place in regards to our treatment of Donor patients is verbally transmitted through training and continuous guidance, and we do not rely on the Donor policy book for reference or use. It is merely there to be compliant.” Please be advised, you must establish and maintain procedures for all steps that you perform in testing, screening, determining donor eligibility, and complying with all other requirements of 21 CFR Part 1271, Subpart C. Establish and maintain means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis.\nPlease note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, this includes donors who were not appropriately tested for relevant communicable disease agents and diseases and\u002For who were not appropriately screened for relevant communicable disease risk factors which includes using previous versions of donor history questionnaires that did not screen for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\nShould the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in Subpart C, 21 CFR Part 1271, as specified in 21 CFR 1271.155. Additional information can be found at Exemptions and Alternatives | FDA. The email address for submissions is HCTPExemptions@fda.hhs.gov.\nPlease note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\nIf you still have embryos in storage for which the donor eligibility requirements under 21 CFR 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine [21 CFR 1271.90(b)] provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\nYou should take prompt action to correct any violations addressed in this letter and prevent their recurrence. Failure to promptly correct any violations may result in regulatory action being initiated by FDA without further notice.\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct any violations, including an explanation of how you plan to prevent them, or similar violations, from occurring again. Additionally, include any documentation necessary to show that correction has been achieved. If you believe that your products are not in violation of the law, include your reasoning and any supporting information for our consideration. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\nIf you have any questions regarding this letter, please contact CBER’s Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Please be advised that only written communications are considered official.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research","Central Coast Multispecialty Medical Group, Inc.","central-coast-multispecialty-medical-group-inc-722521-01292026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcentral-coast-multispecialty-medical-group-inc-722521-01292026","2026-10-26T08:08:13.022809+00:00","2026-02-10","722521","Biologics","Edward J. Ramirez, MD, FACOG","2026-08-19T04:58:19.54+00:00","Via UPS and EMAIL","CBER 26-722521","2026-01-29",12,{"510k":250,"classification":251,"enforcement":252,"event":253,"event_backfill":254,"pma":255,"warning_letter":256},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]